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ABSTRACT 
Compounds are disclosed comprising molecular adjuvants 
having an antigen presenting cell-targeting ligand linked to 
a nicotine hapten. Methods are disclosed for employing the 
compounds as a nicotine vaccine for treatment or prevention 
of nicotine addiction. 
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COMPOSITIONS AND COMPOUNDS FOR USE AS 
MOLECULAR ADJUVANT FOR A NICOTINE 
WACCINE 
0001 Pursuant to 35 U.S.C. S.202(c), it is hereby 
acknowledged that the U.S. Government has certain rights in 
the invention described herein, which was made, in part, 
with funds from the National Institutes of Health, grant 
numbers CA 57362 and CA 36727. 
FIELD OF THE INVENTION 
0002 The present invention relates to the field of vac 
cines and Stimulation of acquired immunity. In particular, 
the present invention provides novel compositions for use as 
a nicotine vaccine. 
BACKGROUND OF THE INVENTION 
0003. The disease consequences of habitual tobacco 
Smoking are irrefutable. Smoking tobacco is a well-estab 
lished causative factor in the pathogenesis of cancers of the 
lung, oral cavity, nasal/sinus cavities, esophagus, and blad 
der. Likewise, inhalation of tobacco Smoke is a major 
etiologic factor in the expression of airway inflammatory 
disorderS Such as chronic obstructive pulmonary disease and 
allergic asthma. Smoking is a well-known risk factor for 
developing coronary heart disease and Stroke. In addition, 
cigarette Smoking contributes to an increase in Systemic 
bone loss and an impairment in the ability to heal bone grafts 
and fractures. SmokerS have less Strong, leSS healthy, min 
eral-deficient bones with reduced bone blood supply and 
fewer and leSS functional bone-forming cells compared to 
their non-Smoking counterparts. Bone loSS in the oral cavity 
asSociated with cigarette Smoking is well documented in the 
dental literature. Cigarette Smoking is a major risk factor for 
periodontitis and has been directly linked to alveolar bone 
loSS, overall tooth loSS, and an impaired healing/fusion of 
dental implants. 
0004. The adverse health effects associated with tobacco 
Smoking also extend to those exposed to Secondary Smoke. 
Chronic exposure to Secondary Smoke is a growing public 
health problem, which has been directly linked to an 
increased incidence of Sudden infant death Syndrome in 
infants of mothers who smoke, low birth weight of infants 
from mothers who Smoked during pregnancy, middle ear 
infections in children, exacerbation of childhood and adult 
asthma, bronchitis, lung/nasal cancers, and ischemic heart 
disease in children and adults. 
0005. As well established as the adverse health conse 
quences of Smoking, So too are the health benefits derived 
from Smoking cessation. Former Smokers, for example, are 
at a significantly lower risk for total mortality in all Smok 
ing-related disease categories relative to their Smoking 
counter-parts. Moreover, the risk for total mortality among 
all disease categories for those who quite Smoking and 
maintain compliance eventually reaches a level comparable 
to those who never Smoked. 
0006 Quitting smoking, however, can be difficult and 
even with Support, only a third of the Smoking population is 
able to quit. Since tobacco dependence results from an 
addiction to nicotine, Strategies aimed at Smoking cessation 
target nicotine's addictive effects. The mainstay of these 
treatments is nicotine replacement therapy with gradually 
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decreasing doses of nicotine delivered via transdermal 
patches, gum, or inhaled nicotine formulations. Although 
this approach has proven beneficial to Some individuals, the 
continued administration of the principal addictive Sub 
stance in cigarette Smoke is not an ideal approach to Smok 
ing cessation and the nicotine itself may exert adverse 
cardiovascular effects. Nicotine addiction is also treated 
with neuroreceptor antagonists/partial agonists to modulate 
neurotransmitter pathways in the brain. Since these recep 
tors and their Signaling pathways also mediate normal brain 
function, Side-effects are common with the use of these 
drugs. Thus, there is a growing need for the development of 
improved Strategies to help individuals quit Smoking and 
maintain long-term compliance in an effort to prevent the 
costly and debilitating diseases caused by Smoking. 
0007 One innovative approach to Smoking cessation and 
long-term compliance is to treat the addictive properties of 
nicotine via immunization with a nicotine vaccine. The 
rationale to this approach is that nicotine-specific antibodies 
generated in response to the vaccine bind circulating nico 
tine outside of the central nervous System and reduce drug 
access to receptor Sites in the brain. This peripheral Site of 
action, along with the high Specificity and affinity of nicotine 
antibodies, makes vaccination an attractive therapeutic 
approach to Smoking cessation. Also, the use of a nicotine 
vaccine has the potential of inducing a “memory' immune 
response, wherein anti-nicotine immunity may be invoked 
when one in exposed to nicotine, an attractive feature for 
ensuring long-term compliance. Moreover, a nicotine vac 
cine would be significantly leSS expensive than conventional 
treatments for nicotine addiction and Smoking cessation. 
0008 Toward that end, drug-specific vaccines have been 
used Successfully to attenuate the behavioral/psychoactive 
effects of cocaine (Fox et al., (1996) Nature Med. 2:1129 
1132), heroin (Killian et al., (1978) Pharmacol. Biochem. 
Behav. 9:34-352), and nicotine (Hieda et al., (1997) J. 
Pharmacol. Exp. Therap. 283:1076-1081; and Pentel et al., 
(2000) Pharmacol. Biochem. Behav. 65:191-198) in rodent 
models. The Success of these applications emanated from the 
vaccine’s ability to induce drug-specific antibodies that 
bound the drug and limited its distribution to the brain where 
the addictive effects are exerted. These anti-drug vaccines 
were composed of the drug conjugated to a large carrier 
protein and immunizations were performed in the presence 
of added adjuvant. The two nicotine Vaccines, for example, 
were made by conjugating 6-(carboxymethylureido)-(+)- 
nicotine to keyhole limpet hemocyanin (KLH) (Hieda et al., 
(1997) J. Pharmacol. Exp. Therap. 283:1076-1081) and 
trans-3'-aminomethylnicotine to Pseudomonas aeruginosa 
expoprotein A (rEPA) (Pentel et al., (2000) Pharmacol. 
Biochem. Behav. 65:191-198). Immunizations were per 
formed in rabbits and rats in the presence of complete and 
incomplete Freund's adjuvant. Under these conditions, both 
nicotine vaccines were capable of inducing nicotine-specific 
antibodies. These antibodies, when used in passive immu 
nizations protocols, were shown to bind plasma nicotine in 
rats, which minimized its adverse cardiovascular effects, and 
decreased nicotine distribution to the brain, which attenu 
ated its psychoactive/behavioral effects. Also, when used in 
active immunization protocols, both vaccines generated 
nicotine-Specific antibodies that were capable of altering the 
plasma and brain concentrations of nicotine in rats. 
US 2005/0O89524 A1 
0009 While the results detailed above illustrate the thera 
peutic potential of a nicotine vaccine for controlling the 
addictive properties of nicotine, these approaches do not 
provide a viable Strategy for Smoking cessation and long 
term compliance. The nicotine-carrier protein designs used 
in these Studies, for example, are limited by their inability to 
direct the nicotine antigen to and activate antigen presenting 
cells (APC), which are essential in processing and present 
ing the antigen to helper T cells. Such APC-mediated 
engagement of helper T cells is critical for the Thelper cells 
to release the cytokines necessary to "help' the antibody 
producing B cells generate the antigen-Specific antibodies. A 
Second limitation to these vaccine designs is their reliance 
on the use of harsh adjuvants (Such as Freund's) to com 
pensate for this lack of APC specificity. These adjuvants 
comprise oily Solutions containing components, Such as 
lipopolysaccharides that Stimulate generalized immune 
responses. A third limitation is the lack of control in attach 
ing the nicotine hapten to the carrier protein in a consistent 
and reproducible manner. Attachment of a Small hapten like 
nicotine to a large carrier protein with many potential 
reactive sites allows for the possibility of hapten-to-carrier 
ratioS varying from lot to lot, causing variation in vaccine 
efficacy. Also, the immunogenic character of the carrier 
protein may be altered or diminished by the random attach 
ment of large numbers of haptens to immunologically 
important Sites. 
0010. Accordingly, a need exists for a nicotine vaccine 
that is capable of causing Smoking cessation and long term 
compliance. The present invention addresses this need by 
providing a composition for use as a nicotine Vaccine 
comprising a molecular adjuvant that is able to deliver both 
Stimulatory Signals and the nicotine antigen to APCs, 
thereby inducing an anti-nicotine antibody response with 
little or no inflammatory Side-effects and without reliance on 
other added adjuvants. 
0.011 Several publications are referenced in this applica 
tion by numerals in parenthesis in order to more fully 
describe the state of the art to which this invention pertains. 
Full citations for these references are found at the end of the 
Specification. The disclosure of each of these publications is 
incorporated by reference herein. 
SUMMARY OF THE INVENTION 
0012. The present invention provides novel compositions 
and methods for delivering Specific antigens to antigen 
presenting cells, and Simultaneously delivering Signals to 
those cells that produce a desired immune response. The 
compositions of the invention are Sometimes referred to 
herein as “APC-targeted activating antigens.” 
0013. According to one aspect of the invention, these 
APC-targeted activating antigens, which elicit an immune 
response mediated by an antigen-presenting cell, comprise 
at least one antigenic moiety functionally linked to at least 
one targeting moiety that binds Specifically to a character 
istic determinant on the antigen-presenting cell. For pur 
poses of the present invention, the term “functionally 
linked' is defined generally as linking of the moieties in Such 
a way that each moiety retains its intended function. This is 
particularly relevant with respect to the targeting moiety, 
which is designed to bind to a characteristic determinant on 
the antigen-presenting cell. 
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0014) Antigen-presenting cells contemplated for target 
ing according to the present invention include, but are not 
limited to, monocytes, dendritic cells, macrophages, B cells 
and some T cells. In preferred embodiments of the invention, 
the characteristic determinant on the selected APC is a cell 
Surface receptor and the targeting moiety of the APC 
targeted antigen is a ligand that binds to the receptor. It is 
particularly preferred that the cell Surface receptor be an 
immunomodulatory receptor. Suitable cell Surface receptors 
include, but are not limited to, C5a receptor, IFNY receptor, 
CD21 (C3d) receptor, CD64 (FcyRI) receptor, and CD23 (FcyRII) receptor. 
0015. One exemplary APC-targeted antigen of the inven 
tion is designed to bind to the C5a receptor, and the targeting 
moiety is a C5a receptor ligand, which is preferably a 
peptide analog of C5a corresponding to the C-terminal 10 
residues of C5a. Another exemplary composition of the 
present invention is designed to bind to the IFNY receptor, 
and comprises a targeting moiety which is a IFNY receptor 
ligand, preferably a peptide analog of IFNY corresponding to 
the N-terminal 39 residues of IFNY. 
0016. The antigenic moiety of the APC-targeted antigens 
of the invention can comprise essentially any antigenic 
Substance, including, but not limited to, peptides and pro 
teins, glycopeptides and glycoproteins, phosphopeptides and 
phosphoproteins, lipopeptides and lipoproteins, carbohy 
drates, nucleic acids and lipids. The APC-targeted antigens 
can comprise more than one antigenic moiety, and likewise 
can comprise more than one targeting moiety. Moreover, 
these moieties can be functionally linked in Several fashions. 
For instance, if “T” represents a targeting moiety, and "Ag” 
represents an antigenic moiety, the APC-targeted antigens of 
the present invention may be oriented as follows: 
0017 Ag-T: 
0.018 T-Ag: 
0019) T-Ag-T; 
0020 T-Ag-T (wherein Ag represents a mul 
tiplicity of antigens. 
0021 Examples of the general formulas set forth above 
include: 
0022 Ag-C5a agonist peptide; 
0023 
0024 
IFNY peptide-Ag; 
IFNY peptide-Ag-C5a agonist peptide. 
0025. According to other aspects of the present invention, 
methods are provided for using the APC-targeted antigens of 
the invention. These include methods of activating an anti 
gen-presenting cell with a targeting ligand and methods of 
eliciting an antigen presenting cell-mediated immune 
response in a Subject in which Such a response is desired. In 
particular, a method is provided to treat or prevent Smoking 
addiction by administration of a therapeutic amount of 
compositions of the invention. General methods of immu 
nizing or Vaccinating a patient requiring Such treatment, 
methods of treating a tumor, and methods for producing 
antibodies Specific for a pre-determined antigen for use as 
research tools or for diagnostic purposes are also contem 
plated to be within the Scope of the present invention. 
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0026. The numerous features and advantages of the com 
positions and methods of the present invention are described 
more fully in the detailed description set forth below. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0.027 FIG. 1 is a graph illustrating the antibody titer 
produced in mice immunized with the indicated peptide 
constructs, as determined by radioimmunoassay, and shows 
the relationship between the amount of I-goat anti-mouse 
antibody bound vs. the dilution factor of mouse sera which 
had been incubated in microtiter wells coated with the 
MUC1 epitope peptide. 
0028 FIG. 2 is a graph illustrating the increase in anti 
body titer in the sera of mice collected either before (pre) or 
after immunization with peptides 3 (YKQGGFLGLYSFKP 
MPLaR) (SEQ ID NO:2) and 4 (YSFKPMPLaRKQGG 
FLGL) (SEQID NO:5) as determined by radioimmunoassay 
and shows the relationship between the amount of I-goat 
anti-mouse antibody bound and the dilution factor of mouse 
Sera which had been incubated in microtiter wells coated 
with MUC1 epitope peptide. Note that peptides 3 and 4 
comprise two moieties, a targeting ligand and an antigen to 
which an immune response is desired. 
0029 FIG. 3 is a graph illustrating the titers of antibody 
classes and Subclasses produced in mice following immu 
nization with peptide 3 (YKQGGFLGLYSFKPMPLaR) 
(SEQ ID NO:2) as determined by ELISA using rabbit 
anti-mouse IgA, IgG1, IgG2a, IgG2b, IgG3, and IgM, 
followed by goat anti-rabbit conjugated to peroxidase and 
detected using p-nitrophenyl phosphate cleavage monitored 
at 405 nm. 
0030 FIG. 4 is a graph illustrating the specificity of 
binding of the antibody Subclasses in Sera from mice immu 
nized with peptide 3 (YKQGGFLGLYSFKPMPLaR) (SEQ 
ID NO:2) as determined by ELISA using binding to micro 
titer wells coated with MUC1 epitope peptide and detection 
with rabbit anti-mouse IgG2a, IgG2b, or IgM followed by 
incubation with goat anti-rabbit conjugated to peroxidase 
and detected using p-nitrophenyl phosphate cleavage moni 
tored at 405 nm. 
0.031 FIG. 5 is a graph showing the HBSAg-specific CTL 
response is induced only by C5-a-active constructs. BALB/c 
mice received three S.c. injections at 21 day intervals using 
50 ug doses of the HBSAg-LMHC class I restricted peptide 
(Sasso) Synthesized with two Arg residues appended to the 
C-terminal end (IPOSLDSWWTSLRR, SEQ ID NO: 18), 
the double-Arg-linked C5a-active construct (IPOSLDSW 
WTSLRRYSFKPMPLaR; SEQID NO: 14) and the double 
Arg-linked C5a-inactive constructs (IPQSLDSWWTSLR 
RYSFKPMPLaRG; SEQ ID NO: 17 and 
YSFKPMPLaRRRIPQSLDSWWTSL; SEQ ID NO: 16). 
Pooled Spleen cell Suspensions were prepared from two mice 
in each group 14 days following the third injection. The cell 
Suspensions were cultured in the presence of the Sasso 
peptide (75 nM) for four days and used as effector cells 
against Cr-labeled P815S (HBSAg transfectant) or P815 
targets. Percent specific lysis of Cr labeled P815S cells at 
various effector to target ratioS is shown and represent the 
means of triplicate determinations. Lysis of Cr labeled 
P815 cells at an effector-to-target ratio of 50:1 was less than 
5% (not shown). The data are representative of three sepa 
rate experiments. 
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0032 FIG. 6 is a graph showing that HBSAg-specific 
CTL responses are induced only by the C5a-active, protease 
Sensitive-linked constructs. BALB/c mice received three S.c. 
injections at 21 day intervals using 50 lug doses of the 
C5a-active constructs in which the HBSAg-L'MHC class I 
restricted peptide (S-39) was covalently attached directly 
to the N-terminus of the C5a agonist (IPOSLDSW 
WTSLYSFKPMPLaR; SEQ ID NO: 13), spaced by two Arg 
residues (IPQSLDSWWTSLRRYSFKPMPLaR; SEQ ID 
NO: 14), or spaced by the furin protease-Sensitive Sequences 
RVRR (SEQ ID NO: 19) (IPQSLDSWWTSLRVRRYS 
FKPMPLaR; SEQ ID NO: 15). Spleen cell suspensions 
were prepared from two mice in each group 14 days fol 
lowing the third injection. The cell Suspensions were cul 
tured in the presence of the Sasso peptide (75 nM) for four 
days and used as effector cells in Cr-release assays against 
P815S or P815 targets. Percent specific lysis of Cr-labeled 
P815S is shown and represent the means of triplicate deter 
minations. Lysis of Cr-labeled P815 cells by these effector 
cells was less than 5% at an effector-to-target ratio of 50:1 
(not shown). 
0033 FIG. 7 is a graph illustrating the antibody reactivity 
of the indicated nicotine vaccine construct. 
0034 FIG. 8, Panel A depicts the total number of dipper 
entries for each treatment regime employed, as indicated and 
Panel B depicts the index of learning-evaluation Score for 
the first light (before Sucrose is given) for each treatment 
regime employed, as indicated. 
0035 FIGS. 9 and 10 collectively depict the ability of the 
nicotine vaccine to generate nicotine Specific antibodies in 
rats immunized with the vaccine. 
DETAILED DESCRIPTION OF THE 
INVENTION 
0036) A major obstacle in the development of vaccines 
and other immunostimulatory agents is the inability of Some 
antigens to be readily taken up and processed by antigen 
presenting cells. Uptake of antigens by APCS is an essential 
Step for Stimulating an effective immune response, Since the 
immune System recognizes the antigen only after it has been 
processed by the APC and presented on the surface of the 
APC in conjunction with the major histocompatibility com 
plex (MHC). 
0037. It is known that APCs, including dendritic cells, 
monocytes, macrophages and B cells, possess functional 
receptors for numerous molecules that modulate the immune 
response. It has now been discovered in accordance with the 
present invention that ligands which bind to these receptors 
can be conjugated to weakly immunogenic antigens for 
example, as a way of delivering antigens to the antigen 
presenting pathway of the APC and Simultaneously activat 
ing the antigen presenting capacity of the APC. Thus, these 
conjugates bind to a receptor on the APC Surface, transduce 
a biological Signal, and are internalized by the APC. The 
antigenic moiety of the conjugate is thereby delivered to the 
antigen presenting pathway of the APC along with the 
simultaneous activation of the APC. 
0038. The above-described conjugates are sometimes 
referred to herein as “molecular adjuvants” or “APC-tar 
geted activating antigens.” The APC-targeted activating 
antigens of the invention are designed to elicit immune 
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responses mediated by one or more types of antigen pre 
Senting cells. Accordingly, an APC-targeted activating anti 
gen comprises at least one antigenic moiety linked to a 
targeting and activating moiety that binds Specifically to at 
least one characteristic determinant on the Selected antigen 
presenting cell type. This binding is followed by internal 
ization of the APC-targeted antigen and results in presenta 
tion of the antigen moiety on the surface of the APC. For 
purposes of the present invention, the term “antigenic moi 
ety' may refer to any Substance to which it is desired that an 
immune response be produced. The Selected antigenic moi 
ety may or may not be capable of eliciting an immune 
response by conventional means. 
0039. The term “determinant” is used herein in its broad 
Sense to denote an element that identifies or determines the 
nature of Something. When used in reference to an antigen 
presenting cell, “determinant’ means that Site on the antigen 
presenting cell which is involved in Specific binding by the 
targeting ligand moiety of the molecular adjuvant of the 
invention. 
0040. The expression “characteristic determinant’ as 
used herein, Signifies an epitope (or group of epitopes) that 
Serves to identify a particular population of antigen present 
ing cells and distinguish it from other antigen presenting cell 
populations. Cell-associated determinants include, for 
example, components of the cell membrane, Such as mem 
brane-bound proteins or glycoproteins, including cell Sur 
face antigens, histo-compatibility antigens or membrane 
receptors. 
0041. The expression “specific binding”, as used herein 
refers to the interaction between the targeting ligand moiety 
and a characteristic determinant on the antigen presenting 
cell population Sought to be activated in accordance with 
this invention, to the Substantial eXclusion of determinants 
present on other cells. 
0.042 Certain exemplary compositions of the invention 
have been Synthesized, and have been shown to elicit 
APC-mediated immune responses in accordance with the 
mechanisms described above. For example, antigenic 
epitopes have been conjugated to the amino-terminal end of 
a C5a decapeptide agonist capable of binding to C5a recep 
tors present on the Surface of many APCs. Mice that were 
inoculated with an epitope of human MUC1 (a cell Surface 
associated mucin) conjugated to Such a C5a agonist exhib 
ited pronounced antibody titers against the MUC1 epitope, 
including high titers of Specific antibodies with isotypes 
IgG2a and IgG2b. Mice that were inoculated with (1) MUC1 
epitope alone, (2) C5a agonist alone, (3) unconjugated 
MUC1 epitope and C5a agonist together, or (4) C5a agonist 
conjugated to MUC1 epitope in a manner in which the 
biological activity of the C5a moiety was blocked, did not 
express a significant Specific immune response. These 
results are described in greater detail in Example 1. Similar 
results were observed with conjugates of C5a agonist to a 12 
kDa polypeptide, Serum amyloid A (SAA), as described in 
greater detail in Example 2. In addition, Example 6 depicts 
the results of the C5a agonist conjugated to various nicotine 
constructs. These data tend to demonstrate the feasibility of 
the invention, which is to use receptor-binding ligands as a 
way to deliver antigens to APCs, with the simultaneous 
activation of APCs by the ligand moiety. 
0043. As described in greater detail below, the C5a 
receptor is only one of many receptors expressed on APCs. 
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This invention encompasses the use of various ligands with 
Selectivity to other receptors that mediate Signal transduction 
events in the APCs, to be used alone or in conjunction with 
C5a agonists to influence the nature of immune response 
generated, i.e., humoral, cellular, Th1, Th2, and the like. 
Vaccines and other immunotherapeutic agents can be pre 
pared with an array of Such targeting moieties that Serve to 
target the antigen moiety to a Specific population of APCs 
and Simultaneously activate these and other cells involved in 
various immune modulatory pathways. 
0044) The detailed description below sets forth preferred 
embodiments for making and using the targeted antigens of 
the present invention. To the extent that Specific compounds 
and reagents are mentioned, these are for the purposes of 
illustration, and are not intended to limit the invention. Any 
biochemical, molecular or recombinant DNA techniques not 
Specifically described are carried out by Standard methods, 
as generally Set forth for example, in Ausubel et al., “Current 
Protocols in Molecular Biology,” John Wiley & Sons, Inc., 
1995. 
0045 I. Preparing APC-Targeted Activating Antigens 
0046 A. Selection of Components 
0047 Antigen presenting cells have various receptors on 
their Surfaces for known ligands. Binding of ligands to these 
receptorS results in Signal transduction events that Stimulate 
immune or tolerance responses. Many of these receptors are 
known to internalize and recycle in the cell. Others are 
Suspected of doing the same. AS Such, these receptors are 
ideal targets for delivering antigens and activation signals 
simultaneously to APCs. 
0048 AS discussed above, APCs include several cell 
types including macrophages, monocytes, dendritic cells, B 
cells, Some T cells and other poorly characterized cell types. 
It is believed that these different classes of APCs can 
produce different types of immune responses. Accordingly, 
by targeting a receptor prevalent on a Specific population of 
APCs, a particular desired immune response may be 
favored. An exemplary list of receptors contemplated for 
targeting in the present invention, and the rationale for their 
selection, is set forth below. These APC receptors are 
particularly appropriate for use in the present invention 
based on the following criteria: they are receptors expressed 
on APCS; the receptors are internalized upon binding of 
ligand; the receptors can transmit Signals in the cells that 
influence antigen processing and presentation by these cells, 
Some of the receptors are believed to be involved in Signal 
ing Th1 type cellular responses, whereas others are predicted 
to generate Th2 type humoral responses. The list Set forth 
below is not exhaustive, but merely representative of the 
type of targeted receptors preferred in practicing the present 
invention. Other receptors, or other cell-Surface character 
istic determinants on antigen presenting cells may also be 
used as targets for the targeted antigens of the present 
invention. The receptor or other characteristic determinant 
need not be directly involved in the immune response. 
0049 C5a receptor. This receptor is preferred for use 
according to the present invention. It is present on PMNs, 
macrophages, dendritic cells, Smooth muscle cells and Some 
mast cells. A number of biological activities have been 
ascribed to C5a, mostly associated with inflammatory and 
immune responses. According to a preferred embodiment, 
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this invention relies on the capability of C5a, as a targeting 
ligand, to Specifically bind to its cognate receptor, So as to 
activate antigen presenting cells, including macrophages, 
monocytes and dendritic cells, through a G protein-mediated 
Signal transduction pathway. Subsequent to Signal transduc 
tion, the receptor/ligand complex is internalized. In the case 
of dendritic cells, C5a has been shown to induce a Th1 type 
response. 
0050. IFNY receptor. The interferon Y receptor is 
expressed on macrophages, monocytes, dendritic cells, other 
APCs, some B cells, fibroblasts, epithelial cells, endothe 
lium, and colon carcinoma cells. IFNY binding to its receptor 
induces macrophage and dendritic cell activation, B cell 
differentiation, and expression of MHC class I and class II 
molecules in many cell types. The receptor is involved in 
Signal transduction pathways. IFNY is mainly produced in 
the body by activated T cells, particularly during the gen 
eration of Th1 type response. It is also produced by CD8+ 
cytotoxic T lymphocytes following recognition of antigen 
associated with MHC class I and by natural killer cells 
stimulated with TNFC. and microbial products (Barclay et al. 
1993.). 
0051 CD 21 (C3d receptor). CD 21 is the receptor for the 
C3d complement fragment. It is a receptor for the Epstein 
Barr virus and may be an important interferon C. receptor 
(Barclay et al., Supra). CD 21 is expressed on B cells, 
follicular dendritic cells, other APCs, pharyngeal and cer 
Vical epithelial cells, and Some thymocytes. It is involved in 
activation and proliferation of B cells through a signal 
transduction mechanism and it has been associated with 
increases in antigen presentation activities by those cells. 
0.052 CD 64 (FcyRI receptor). CD 64 is a high affinity 
receptor for IgG, the only known receptor that binds mono 
meric IgG (Barclay et al., Supra). This receptor is found on 
macrophages, monocytes and other immune cell populations 
treated with IFNY. The IgG binding site resides in the CH2 
domain. IFNY Strongly upregulates expression of this recep 
tor, which is the primary receptor involved in antibody 
dependent cell mediated cytotoxicity reaction, and phago 
cytic activity by these cells. 
0053 CD (Fce RII receptor). CD23 is a low affinity 
receptor for IgE (not related to the high affinity IgE receptor 
found on basophils and mast cells). It is found on some B 
cell populations, macrophages, eosinophils, platelets, and 
dendritic cells (Barclay et al., Supra). CD 23 mediates IgE 
dependent cell mediated cytotoxicity and phagocytosis by 
macrophages and eosinophils, and binding of IgE immuno 
complexes increases the efficiency of antigen processing and 
presentation by Some ACPS, through a signal transduction 
mechanism that includes the p59 fyn tyrosine kinase. The 
ligand for CD 23 is the Ce3 domain of IgE. 
0.054 As mentioned above, the APC-targeted antigens of 
the present invention comprise at least one antigenic moiety 
and at least one targeting moiety. The targeting moiety can 
be derived from naturally-occurring ligands for a Selected 
receptor on an APC, or analogs and derivatives of Such 
ligands. For instance, the C5a receptor is a preferred recep 
tor for use in practicing the present invention. Naturally 
occurring C5a can be utilized as the targeting moiety in the 
APC targeted activating antigens of the invention. However, 
native C5a is not preferred for use as the targeting moiety as 
it induces a myriad of pro-inflammatory responses which 
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may be undesirable Side effects. In particularly preferred 
embodiments of the invention, C-terminal C5a agonist ana 
logs capable of C5a receptor binding and Signal transduction 
in a response Selective manner are utilized. Such analogs are 
described in detail in U.S. Pat. Nos. 5,96,230 and 5,942,599 
to SanderSon et al., and commonly-owned U.S. application 
Ser. No. 08/299,285, the entire disclosure of which is 
incorporated by reference herein. 
0055 An exemplary C5a C-terminal decapeptide agonist 
preferred for use in the present invention is: 
YSFKPMPILaR (SEQ ID NO: 1) 
0056. This decapeptide is a potent agonist of naturally 
occurring C5a, and is preferred to naturally occurring C5a 
because its Small Size contributes to ease of Synthesis and 
solubility. Moreover, these conformationally biased peptides 
are stable toward Serum carboxypeptidase digestion, eXpress 
level biological selectivity, and have been shown to be 
non-toxic in high concentrations in athymic mice. 
0057 Peptide analogs of naturally-occurring interferon Y 
are also contemplated for use in the present invention. 
Peptides corresponding to the amino terminal 39 amino 
acids of IFNY have been shown to compete for binding with 
native IFNY. Antibodies against this domain block biological 
activity, and removal of the first 10 amino terminal residues 
eliminates biological activity. This Suggests that binding of 
IFNY to its cognate receptor is mediated by this portion of 
the molecule. Accordingly, peptides based on this domain 
are contemplated to be of use for delivering antigens to 
APCs expressing IFNY receptors. In this regard, it should be 
noted that human and mouse IFNY are absolutely species 
Specific in binding and activity. Consequently, for Stimulat 
ing APC-mediated immune responses in mice, the mouse 
peptides will be utilized, and the human peptide will like 
wise be utilized for stimulating APC-mediated immune 
responses in humans. The mouse IFNY 39 amino acid 
peptide analog is composed of the following Sequence: 
HGTVIESLESLNNYFNFFGIDWEEKSLFLDIWRNWQKDG 
(SEQ ID NO : 3) 
0058. The human IFNY 39 amino acid peptide analog is 
composed of the following Sequence: 
QDPYWKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEE 
(SEQ ID NO : 4) 
0059 Another ligand contemplated for use in the present 
invention is the C3dG component of complement. This 
component is a 348 residue fragment derived by proteolytic 
cleavage from the C3b precursor (residue 955-1303 of C3; 
Swissprot accession p01024). C3dG can be converted to 
C3d (residues 1002-1303) and C3g (residues 955-1001). 
C3dG and C3d remain associated with non-activator Sur 
faces and Serve as opSonins for phagocytosis by macroph 
ages and other antigen presenting cells. Cd 21 is the C3dG 
and C3d receptor. 
0060. The above-listed ligands exemplify the type of 
ligand preferred for practice of the present invention. How 
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ever, it will be appreciated by those skilled in the art that 
other ligands may be utilized as the targeting moiety of the 
APC-targeted antigens of the invention. These include 
ligands that are already known in the art, as well as ligands 
that may be discovered and developed henceforth. Antibod 
ies or antibody fragments also may be used to target APC 
Specific cell Surface antigens. 
0061 The type of antigen that can be chosen as the 
antigenic moiety in the present invention can be any peptide, 
polypeptide or derivative thereof for which an immune 
response on antibody production is desired. These include 
but are not limited to, peptides, polypeptides (i.e. proteins) 
and derivatives thereof, Such as glycopeptides, phosphopep 
tides and the like. Synthetic peptide and polypeptide deriva 
tives or analogs, or any other Similar compound that can be 
conjugated to a receptor-targeting moiety can be used in the 
present invention. Moreover, these peptides, proteins and 
derivatives may comprise Single epitopes or multiple 
epitopes for generating different types of immune responses. 
Indeed, if an entire protein is conjugated to a targeting 
moiety, this protein is likely to comprise numerous epitopes, 
which may vary depending upon the Solvent conditions and 
their effect on Secondary and tertiary Structure of the protein. 
Carbohydrates, nucleic acids and other non-protein Sub 
stances also may be used as the antigenic moiety. Methods 
are available in the art for conjugating these Substances to 
the peptide or protein targeting moiety. 
0.062 Other Substances that can be used as the antigenic 
moiety include Small molecules, Such as (1) metabolic 
byproducts (especially those that are toxic); (2) various 
environmental toxins or irritants (e.g., aromatic hydrocar 
bons, asbestos, mercury compounds and the like); (3) drugs 
(e.g., cocaine, heroin, nicotine, etc.) for treating addiction; 
and (4) venoms from Snakes, Spiders, or other organisms. 
Many of these kinds of Small molecules are non-antigenic or 
weakly antigenic, So would be appropriate candidates for 
use in the present invention. Example 6 below illustrates the 
use of nicotine as the antigenic moiety. 
0.063. In preferred embodiments of the invention, the 
antigenic moiety comprises agents that are weakly antigenic 
or non-antigenic under currently available immunization 
conditions. For example, nicotine falls into this category 
because it is a Small organic compound that is non-antigenic 
under normal conditions. Equally, many tumor-associated 
antigens fall into this category, because the antigens are also 
expressed by normal cells. Therefore, immunological toler 
ance to Such molecules makes it difficult to Stimulate 
responses against Such antigens. Other proteins that fall into 
this category include naturally occurring proteins form one 
Species (e.g., human) for which it would be desirable to 
produce antibodies in another Species but which are recal 
citrant to antibody generation in the other species. 
0.064 One well-characterized tumor antigen is a cell 
Surface-associated mucin that is highly overexpressed and 
differentially glycosylated by different adenocarcinomas, 
including breast, pancreas, lung and prostate carcinomas. 
Aberrant glycosylation of MUC1 by adenocarcinomas 
results in the addition of Some blood group carbohydrate 
antigens to this core protein and the exposure of epitopes 
which have been detected by monoclonal antibodies on the 
core protein that are not exposed on forms of this protein 
produced by normal epithelial cells. A full-length cDNA 
Apr. 28, 2005 
Sequence of human mucin-1 (MUC1) revealed an encoded 
protein with an average length of approximately 1200 amino 
acids (depending on the length of the tandem repeat allele) 
with Several obvious domains: an amino terminal Signal 
peptide; a large domain made up of multiple identical 20 
amino acid tandem repeats flanked by Several repeats that 
contain degenerate Sequences, a hydrophobic-spanning 
domain of 31 amino acids, and a cytoplasmic domain of 69 
amino acids at the carboxyl terminus. The most well 
characterized tumor associated epitopes described to date for 
MUC1 are found in the tandem repeat domain. These 
include carbohydrate Structures and protein Structures. 
MUC1 tumor associated epitopes are well characterized, and 
thus have been proposed to be used for the production of 
tumor vaccines using conventional methods. Exemplary 
compositions of the present invention comprise MUC1 
epitopes, Such as those Set forth below, as the antigenic 
moiety of the APC-1 targeted antigens of the invention, to 
demonstrate the potential of the present invention as potent 
tumor vaccines. 
0065. MUC1 epitope predicted to bind class I molecules 
of the H-2K' type has sequence homology to the juxtamem 
brane region of MUC1; 
YKQGGFLGL (SEQ ID NO: 6) 
0066 MUC1 tandem report has the sequence: 
GWTSAPDTRRAPGSTAPPAH (SEQ ID NO: 7) 
0067. The components comprising the APC-targeted 
antigens of the invention can be made Separately, then 
conjugated. For example, a Small peptide analog, Such as the 
above-described C5a agonists, may be produced by peptide 
Synthetic methods, and conjugated to a protein which has 
been purified from naturally occurring biological Sources. 
Alternatively proteins engineered for expression via recom 
binant methods may be used. Additionally, targeted antigens 
comprising peptide components (i.e., a peptide antigenic 
epitope conjugated to a peptide receptor ligand) can by 
Synthesized in tandem by peptide Synthetic chemistry 
according to known methods and as described in greater 
detail below. Finally, targeted antigens of the invention 
comprising two larger polypeptide moieties (i.e., a large 
polypeptide antigen linked to a large ligand) can be made by 
recombinant techniques. For example, DNA molecules 
encoding both components can be ligated together by 
recombinant means, then expressed as the conjugated fusion 
protein. Methods of making these different types of com 
positions are Set forth in greater detail below. 
0068 B. Peptides 
0069 Oligopeptides required for the present invention 
may be prepared by various Synthetic methods of peptide 
Synthesis via condensation of one or more amino acid 
residues, in accordance with conventional peptide Synthesis 
methods. Preferably, peptides are Synthesized according to 
Standard Solid-phase methodologies, Such as may be per 
formed on an Applied Biosystems Model 430A peptide 
Synthesizer (Applied BioSystems, Foster City, Calif.), 
according to manufacturer's instructions. Other methods of 
Synthesizing peptides or peptidomimetics, either by Solid 
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phase methodologies or in liquid phase, are well known to 
those skilled in the art. When solid-phase synthesis is 
utilized, the C-terminal amino acid is linked to an insoluble 
resin Support that can produce a detachable bond by reacting 
with a carboxyl group in a C-terminal amino acid. One 
preferred insoluble resin Support is p-hydroxymethylphe 
noxymethyl polystyrene (HMP) resin. Other useful resins 
include, but are not limited to: phenylacetamidomethyl 
(PAM) resins for synthesis of some N-methyl-containing 
peptides (this resin is used with the Boc method of solid 
phase synthesis; and MBHA (p-methylbenzhdrylamine) res 
ins for producing peptides having C-terminal amide groups. 
0070. During the course of peptide synthesis, branched 
chain amino and carboxyl groupS may be protected/depro 
tected as needed, using commonly-known protecting 
groups. In a preferred embodiment, NC.-amino groups are 
protected with the base-labile 9-fluorenylmethyloxycarbo 
nyl (Fmoc) group or t-butyloxycarbonyl (Boc groups). Side 
chain functional groups consistent with Fmoc Synthesis may 
be protected with the indicated protecting groupS as follows: 
arginine (2,2,5,7,8-pentamethylchroman-6-sulfonyl); aspar 
agine (O-t-butyl ester); cysteine glutamine and histidine 
(trityl); lysine (t-butyloxycarbonyl); Serine and tyrosine 
(t-butyl). Modification utilizing alternative protecting 
groups for peptides and peptide derivatives will be apparent 
to those of skill in the art. 
0071 C. Proteins 
0.072 Full-length proteins for use in the present invention 
may be prepared in a variety of ways, according to known 
methods. Proteins may be purified from appropriate Sources, 
e.g., human or animal cultured cells or tissues, by various 
methods Such as gel filtration, ion eXchange chromatogra 
phy, reverse-phase HPLC and immunoaffinity purification, 
among others. However, due to the often limited amount of 
a protein present in a Sample at any given time, conventional 
purification techniques are not preferred in the present 
invention. 
0073. The availability of nucleic acids molecules encod 
ing a protein enables production of the protein using in Vitro 
expression methods known in the art. For example, a cDNA 
or gene may be cloned into an appropriate in vitro transcrip 
tion vector, such a pSP64 or pSP65 for in vitro transcription, 
followed by cell-free translation in a suitable cell-free trans 
lation System, Such as wheat germ or rabbit reticulocytes. In 
Vitro transcription and translation Systems are commercially 
available, e.g., from Promega Biotech, Madison, Wis. or 
BRL, Rockville, Md. 
0.074 Alternatively, according to a preferred embodi 
ment, a Selected peptide or protein may be produced by 
expression in a Suitable procaryotic or eucaryotic System. 
For example, a DNA molecule, encoding a peptide or 
protein component of the invention, or an entire composite 
targeted antigen of the invention, may be inserted into a 
plasmid vector adapted for expression in a bacterial cell, 
Such as E. coli, or into a baculovirus vector for expression 
in an insect cell. Such vectors comprise the regulatory 
elements necessary for expression of the DNA in the host 
cell, positioned in Such a manner as to permit expression of 
the DNA in the host cell. Such regulatory elements required 
for expression include promoter Sequences, transcription 
initiation Sequences and, optionally, enhancer Sequences. 
0075) A peptide or protein produced by gene expression 
in a recombinant procaryotic or eucaryotic System may be 
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purified according to methods known in the art. In a pre 
ferred embodiment, a commercially available expression/ 
Secretion System can be used, whereby the recombinant 
protein is expressed and thereafter Secreted from the host 
cell, So as to be readily purified from the Surrounding 
medium. If expression/Secretion vectors are not used, an 
alternative approach involves purifying the recombinant 
protein by affinity Separation, Such as by immunological 
interaction with antibodies that bind specifically to the 
recombinant protein. Such methods are commonly used for 
isolating peptides and proteins. 
0076 D. Linking Separately-Made Proteins and/or Pep 
tides 
0077. In an alternative embodiment, protein and/or pep 
tide components of the invention are Synthesized Separately, 
then conjugated using Standard methods known by those 
skilled in the art. For example, a Synthetic peptide may be 
chemically coupled to a protein using m-maleimidobenzoyl 
N-hydroxysuccinimide ester (MBF). This reagent cross 
links amino- and carboxy-terminal thiol groups in the pep 
tide with lysine Side chains present in the protein. 
Alternatively, a Synthetic peptide may be coupled to a 
protein using glutaraldehyde, a common croSS-linking agent. 
Another methods for chemically coupling a peptide to a 
protein is through the use of carbodiimide and 1-(3-dim 
ethylaminopropyl)-3-ethylcarbodiimide methiodide (EDC). 
AS described in greater detail in Example 2, this method was 
used to conjugate a C5a C-terminal decapeptide analog to 
serum anyloid A (SAA). Methods for joining two proteins 
together are also available. 
0078. The peptides or proteins of the invention, prepared 
by the aforementioned methods, may be analyzed according 
to Standard procedures. For example, they may be Subjected 
to amino acid Sequence analysis, mass spectra analysis or 
amino acid compositional analysis according to known 
methods. 
0079 E. General Formulae and Exemplary Compositions 
of the Invention 
0080. The APC-targeted antigens of the invention can 
comprise one or more antigenic moieties, and likewise can 
comprise one or more targeting moieties. Moreover, these 
moieties can be functionally linked in Several ways. For 
instance, if “T” represents a targeting moiety, and "Ag” 
represents an antigenic moiety, the APC-targeted antigens of 
the present invention may be organized as follows: 
0081 Ag-T: 
0082 T-Ag: 
0083) T-Ag-T; 
0084 T-Ag-T (wherein Ag represents a mul 
tiplicity of antigens, 
0085 Examples of the general formulas set forth 
above include: 
0086 Ag-C5a agonist peptide; 
0087 
0088) 
IFNY peptide-Ag; 
IFNY peptide-Ag-C5a agonist peptide. 
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0089. Other representative compositions of the invention 
include: 
0090 MUC1 Class I binding epitope -C5a agonist 
C-terminal peptide 
0091 Murine or human IFNY peptide-MUC1 
Class I binding epitope 
0092 Murine or human IFNY peptide-MUC1 tan 
dem repeat 
0093 MUC1 Class I epitope-C3dG peptide 
0094 SAA-K-Ahx-C5a C-terminal peptide (Ahx= 
eamino hexanoic acid). 
0.095. It will be appreciated by persons skilled in the art 
that the APC-targeted activating antigens of the invention 
may be adapted for inclusion of large or complex antigens. 
This may be accomplished, for example, by inclusion of a 
“spacer” (Such as the K-AhX Spacer moiety in the exemplary 
compound above) between the antigen and the targeting 
moiety. Such chemical modifications are familiar to bio 
chemists. 
0.096 Cleavable linkers. In addition to the foregoing sorts 
of Spacers and linkers, it has also been discovered in 
accordance with the present invention that introduction of a 
cleavage-prone oligopeptide between the targeting moiety 
and the antigen can improve the immunogenicity of the 
molecule. For instance, as described in greater detail in 
Example 5, an Arg-Arg dipeptide or an Arg-Val-Arg-Arg 
(SEQ ID NO: 19) tetrapeptide between the C5a peptide 
analog, YSFKPMPLaR (SEQ ID NO: 1) and a cytotoxic T 
lymphocyte (CTL) epitope of hepatitis B virus surface 
antigen was found to robustly elicit a CTL response to the 
antigen in mice, in the absence of added adjuvant. The 
Arg-Arg dipeptide adds a Scissile bond that is Susceptible to 
cleavage or cleavage by trypsin-like proteases (e.g., Subtili 
sin). The Arg-Val-Arg-Arg (SEQ ID NO: 19) tetrapeptide 
imbues Sensitivity to cleavage by furin (another trypsin-like 
protease). While not intending to be limited by an particular 
explanation of the underlying mechanism by which the 
robust CTL response was elicited, it is believed that the 
Arg-Arg or Arg-Val-Arg-Arg (SEQ ID NO: 19) protease 
Sensitive linker peptides facilitate cleavage of the molecular 
adjuvant within the APC, thereby more expeditiously free 
ing the antigen for further processing and presentation of the 
APC cell Surface. 
0097. Other scissile bond dipeptides or other oligopep 
tides also can be inserted between the targeting moiety and 
the antigen. These include residues to create a peptide 
bond(s) that is Susceptible to other cytoplasmic proteases or 
proteases found within any of the intracellular antigen 
processing organelles. Preferred Sites comprise dibasic 
dipeptides (i.e., various dipeptide permutations comprising 
Arg, Lys or His) or oligopeptide cleavage sites for the 
trypsin family or proteases. 
0.098 Another option is the creation of a dipeptide scis 
Sile bond that is Susceptible to acid-catalyzed hydrolysis 
when exposed to the acidic conditions typically found within 
intracellular endoSomal/lysosomal compartments of an anti 
gen presenting cell (APC). In addition, other epitope-target 
ing moiety linkages are contemplated to have a similar 
utility in the efficiency of processing by APCs. These 
include Sequences that are known or Suspected to facilitate 
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or enhance 1) the transport/update of epitope constructs into 
the rough endoplasmic reticulum (RER), 2) the association 
of epitope to MHC class I and/or class II determinants, 3) 
transport of epitope through the cis, medial, and trans Golgi 
apparati, and 4) entry into transport vehicles associated with 
MHC class I. 
0099 Thus, a variety of “cleavable linkers” can be 
inserted between the targeting moiety and the antigen to 
facilitate processing of the antigen by the antigen-presenting 
cells. As used herein, the term “cleavable linker” refers to 
any linker between the antigenic moiety and the targeting 
moiety that promotes or otherwise renders the molecular 
adjuvant more Susceptible to cleavage (by proteases, low pH 
or any other means that may occur within or around the 
antigen-presenting cell) and, thereby, processing by the 
antigen-presenting cell, than an equivalent molecular adju 
Vant lacking Such a cleavable linker. 
0100 II. Uses of APC-Targeted Activating Antigens 
0101 The APC-targeted activating antigens of the 
present invention have broad potential for clinical applica 
tions in humans and animals. AS discussed above, a signifi 
cant impediment to the development of vaccines and other 
immunotherapeutic agents is the apparent inability of par 
ticular antigens to be readily taken up and processed by 
antigen presenting cells. The compositions of the invention 
facilitate the Specific delivery of an antigen to a population 
of antigen presenting cells, whereupon the delivery mecha 
nism (e.g., using as the targeting moiety a receptor ligand 
capable of transducing a biological signal) simultaneously 
activates the antigen presenting pathway. of the APC. Thus, 
the present invention enables development of vaccines and 
other immunothereapeutics that can Specifically target any 
peptide antigen or other antigenic Structure covalently 
attached to a ligand for a receptor present on an antigen 
presenting cell. It is believed that antigens linked to ligands 
that Selectively bind to and activate a particular population 
of APCs can not only generate an immune response, but can 
influence the nature of the immune response that is gener 
ated. Thus, immune responses that favor antibody, cellular, 
Th1 or Th2 responses, respectively, may be Selectively 
generated. Vaccines may also be developed with an array of 
Such targeting moieties thereby Serving to target a Selected 
antigen or antigens to Several populations of APCs and 
Simultaneously activate these and other cells involved in 
various immune modulatory pathways. 
0102) The ability to generate either antibody or cell 
mediated immune responses against different specific anti 
gens has broad general applicability, and it is anticipated that 
the APC-targeted antigens of the invention will be extremely 
useful for these purposes. For example, antibody responses 
have been shown to be capable of protecting against differ 
ent Viral or bacterial infection, and antibodies are known to 
inactivate different toxins or toxic compounds that may 
affect the well being of humans or animals. Different cell 
mediated immune responses can provide protection against 
Viral or other intracellular pathogens, and can play a role in 
Some anti-tumor responses. It is believed that different 
antigen presenting cells and the context in which these cells 
are stimulated to present antigen (co-stimulation mediated 
by different ligand-receptor interactions) are important fac 
torS determining the nature of the above responses. 
0103) The targeted antigens of the present invention 
should find particular utility in the development of active 
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Specific immunotherapeutic agents (i.e., cancer “vaccines”) 
based on cancer-associated antigens. For example, it has 
been hypothesized that induction of Strong cell-mediated 
immune responses (involving Th1 cells and/or cytotoxic T 
lymphocytes) would provide the most effective protection 
against various forms of cancer. A vaccination Strategy 
utilizing the APC-targeted antigens of the invention can be 
designed to induce this type of response. In this regard, it is 
known that stimulation with some cytokines (IL-12, IFNY) 
can induce predominantly Th1 type responses over Th2 type 
responses for certain antigens. 
0104. As a step toward developing anti-cancer Vaccines 
for clinical use, the compositions of the invention can be 
used to advantage as research tools to further explore the 
effect of stimulating a certain population of APCs with a 
tumor antigen and determining the effect on an anti-tumor 
immune response. To this end, it should be noted that the 
present application exemplifies targeted antigens comprising 
an epitope of a particular tumor-specific antigen, Mucin-1. 
0105 Previous tumor vaccine formulations that aim to 
immunize patients with compounds that are identical to 
compounds already produced by tumors have proven to be 
of limited value, probably because tumors that progreSS have 
been Selected for their lack of immunogenicity in their 
respective host (e.g., the host is tolerant to existing tumor 
antigens). Thus, one important challenge of producing effec 
tive tumor vaccines is generating reagents that counteract 
immunological tolerance to tumor-associated antigens. One 
purpose of the APC-targeted antigens described above is to 
induce in the immunized individual a is response against 
their tumor that is similar to that Seen in individuals under 
going allograft rejection. In other words, the goal is to 
induce an autoimmune reaction against the tumor that is 
capable of destroying the tumor. The immunological param 
eters that regulate tolerance to tumor antigens are not well 
understood; nonetheless the compositions described herein 
have the potential to counteract this tolerance and thus 
induce Specific immune responses that mediate tumor rejec 
tion. 
0106 The targeted antigens of the present invention will 
also find broad utility in the production of antibodies for use 
as immunodiagnostic and immunotherapeutic agents. For 
immunodiagnostic purposes, antibodies are widely used in 
various quantitative and qualitative assays for the detection 
and measurement of biological molecules associated with 
diseases or other pathological conditions. For reasons that 
often are not well understood, it is sometimes difficult to 
generate antibodies against certain biological molecules 
using conventional means. The compositions of the present 
invention provide an alternative means for inducing an 
animal to produce antibodies against a weakly-antigenic or 
non-antigenic Substances. The utility of the compositions of 
the invention in this regard is shown clearly in Example 2, 
below, in connection with Serum amyloid A. The appearance 
and abundance of this protein in the body is Strongly 
correlated with Systemic inflammatory StreSS, which is a 
condition that is very difficult to quantitate. It is believed that 
quantitative assays for SAA levels would be an excellent 
indicator of general, Systemic inflammation; therefore it 
would be of benefit to generate antibodies against the protein 
in a non-human Species. This protein has proved particularly 
recalcitrant to the generation of antibodies using conven 
tional measures. AS described in Example 2, a targeted 
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antigen comprising SAA conjugated to a C5a peptide ligand 
produced a significant antibody response in mice injected 
with the conjugated molecule. In a Similar fashion, targeted 
antigens comprising any Weakly-antigenic or non-antigenic 
component of interest could be made and used to produce 
Specific antibodies in laboratory animals, for use as immu 
nodiagnostic reagents. 
0107 Antibodies for use as immunotherapeutic agents 
can also be generated using the compositions of the inven 
tion. AS one example, there has been a great deal of recent 
interest in developing reagents capable of down-regulating 
or inhibiting the complement cascade to modulate local and 
Systemic inflammatory responses. To this end, the C3a 
convertase, which is active early in the cascade, could 
provide an ideal target for complement inhibition. C3a 
convertase cleaves the peptide C3 into two components, C3a 
and C3b, and therefore must be able to access the cleavage 
site on C3 in order to accomplish the result. Antibodies 
directed toward the C3a-C3b cleavage site are expected to 
be effective in blocking access of C3a convertase to the 
cleavage Site, thereby inhibiting this early Step in the 
complement cascade. Such antibodies may be generated 
using a targeted antigen of the invention comprising, as the 
antigenic moiety, the short peptide Sequence comprising the 
C3a/C3b cleavage Site. The Sequence could then be conju 
gated to an appropriate targeting moiety, Such as the C5a 
C-terminal decapeptide agonists exemplified herein. Thus, 
the compositions would be useful to generate an immuno 
therapeutic agent (e.g., an antibody that blocks the activity 
of C3a convertase) for treating an adverse inflammatory 
condition. 
0108) 
0109. In a particularly preferred use, as stated above, the 
compositions of the invention may be utilized to treat the 
addictive properties of nicotine addiction via immunization 
with a nicotine vaccine. The rationale to this approach is that 
nicotine-Specific antibodies generated in response to the 
vaccine bind circulating nicotine outside of the central 
nervous System and reduce drug access to receptor Sites in 
the brain. This peripheral Site of action, along with the high 
Specificity and affinity of nicotine antibodies, makes vacci 
nation an attractive therapeutic approach to Smoking ceSSa 
tion. Also, the nicotine vaccine has the potential of inducing 
a “memory immune response, wherein anti-nicotine immu 
nity may be invoked when one in exposed to nicotine, an 
attractive feature for ensuring long-term compliance. 
III. Nicotine Vaccine. 
0110 Toward that end, the composition employed as a 
nicotine vaccine may comprise any molecular adjuvant 
described herein linked to a nicotine hapten in any manner 
described herein. Typical embodiments of Such composi 
tions include the following: 
(a) Nic-YSFKPMPLaR (Nic-SEQ ID NO: 1); 
(b) Nic-YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID NO: 2); 
(c) Nic-YKQGGFLGLRRYSFKPMPLaR (Nic-SEQ ID NO: 20); 
(d) Nic 
YKGGFLGLYSFKPMPLaR (Nic-SEQ ID NO:2); 
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-continued 
(e) Nic 
YKQGGFLGLRRYSFKPMPLaR (Nic-SEQ ID NO:20 ); 
(f) Nic 
Nic-YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID NO: 2); and 
(g) Nic 
Nic-YKQGGFLFLRRYSFKPMPLaR (Nic-SEQ ID NO: 20). 
0111. In one embodiment, the nicotine vaccine comprises 
composition (a) above and is the molecular adjuvant 
YSFKPMPLaR (SEQ ID NO:1) covalently modified on the 
N-terminal end with a nicotine hapten. In yet another 
embodiment, the nicotine vaccine comprises any one of 
compositions (b)-(g) and is composed of the B cell epitope 
from the juxta-membrane region of MUC1 (YKQGG 
FLGL)(SEQ ID NO:6) modified with nicotine at the N-ter 
minus of the peptide and/or the C-amino moiety of the 
indicated Lys residue. In vaccine compositions (c), (e), and 
(g) the nicotine-modified B cell epitope is separated with the 
protease-Sensitive, dibasic Arg-Arg (RR) Sequence. In yet 
another exemplary embodiment, the nicotine vaccine com 
positions detailed in Example 6 may be employed. 
0112 i. Peptide Synthesis and Nicotine Attachment. Oli 
gopeptides required for the present invention may be pre 
pared by various synthetic methods of peptide synthesis via 
condensation of one or more amino acid residues, in accor 
dance with conventional peptide Synthesis methods. In one 
preferred embodiment, as more generally described above, 
the peptides may be Synthesized by Standard Solid phase 
orthogonal methods in which the reactive Side-chain groups 
of the residues are protected with acid-labile groupS and the 
amino group of each reside is protected with the base-labile 
9-fluorenylmethoxycarbonyl (Fmoc) group. In this method, 
Synthesis begins with the fully protected C-terminal residue 
attached to an insoluble resin Supported via its carboxyl 
group. The Fmoc group of this first residue is deprotected 
with base, thereby exposing only the amino group for a 
coupling reaction with the carboxyl group of the Second 
amino acid residue to form an amide (peptide) bond between 
the first and Second residues. The Fmoc group on the Second 
residue may be deprotected with base exposing this resi 
due's amino group for reaction with the carboxyl group of 
the third residue. This cycle of deprotection and coupling is 
repeated until the full peptide Sequence is completed. A final 
deprotection of the last Fmoc group with base exposes the 
peptide's N-terminal amino group and all other reactive 
Side-chain groups in the peptide remain protected. This free, 
N-terminal amino group may then Serve as at least one site 
to which a nicotine molecule can be attached via an amide 
linkage when the nicotine molecule is modified to provide 
the complementary carboxyl group as detailed below. 
0113. In yet another embodiment, synthesis of the peptide 
is performed Such that it provides carboxyl groups for 
nicotine attachment via an amide linkage when the nicotine 
molecule is modified to provide the complementary amino 
group as detailed below. Any one of the free amino groups 
generated by the above route on the protected peptide can be 
converted into a carboxyl group by reaction with, for 
example, Succinic anhydride or any other appropriate 
reagent. Other free carboxyl groups on the peptide could be 
10 
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provided by the side-chains of Asp or Glu residues. These 
residues can come from either the naturally occurring resi 
dues in the Sequence or they can be added Specifically for 
this reason during the course of peptide Synthesis by any 
generally known method. 
0114. After its synthesis, the resin-attached, fully pro 
tected, nicotine-modified peptide is then Subjected to mild 
acidolysis to remove the Side-chain protecting groupS and 
cleave the peptide from the resin according to Standard 
methods. All peptides may then be purified by preparative 
and analytical reverse-phase HPLC according to generally 
known methods and characterized by amino acid composi 
tional analysis and mass Spectrometry. 
0115 ii. Modification of Nicotine. Given the ease with 
which free amino and carboxyl groups can be generated at 
various sites on the peptide as detailed above, one method of 
attaching nicotine haptens to the peptide is via the formation 
of an amide bond provided that the nicotine molecule is 
modified So that it presents the complementary carboxyl or 
amino groups. An amide bond linkage between nicotine and 
the peptide is attractive because it maintains the same type 
of covalent linkages that already exist in the peptide, thus 
minimizing the possibility of introducing new immunogenic 
character to the antigen of interest or directing immunogenic 
recognition away from the antigen of interest. 
0116. Accordingly, in one embodiment, nicotine may be 
modified to express the complementary carboxyl or amino 
groups necessary for amide linkage to the peptide by the 
Synthetic routes described below. These routes will generate 
the carboxyl and amino groups on different Sites of the 
nicotine molecule, which allows the opportunity of conju 
gating nicotine to various Sites on the peptide Such that 
different potential antigenic regions of the nicotine molecule 
can be exposed and presented. 
0117 The nicotine haptens, NH1 and NH2, described in 
Sections a. and b. below each express carboxylic acid 
functional groups to allow amide bond formation with either 
the N-terminal or LyS e-amino groups of the peptide. 
NH1 
HOOC 
CH 
N 
NH2 
21 s N 
N N-cool N 
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-continued 
HN-N 
y 
X xx w 21 
Nicotine hapten (NH) strucutures showing the location of the 
carboxyl and amino functional groups for linking to the peptide 
N 
CH 
0118 a. NH1: Carboxyl Modification of the pyridine 
Ring of Nicotine. As shown in Scheme 1 below, in one 
embodiment, the synthesis of NH1 begins with treatment of 
commercially available ethyl-5-bromo-nicotine (1) with 
1-vinylpyrrolidinone anion followed by acid-catalyzed 
decarboxylation and ring closure to give 5-bromomyOSmine 
(2). Reduction of 2 with NaBH/CBZ-D-proline followed by 
N-methylation and resolution with dibenzoyl-L-tartaric acid 
will provide (S)-5-bromonicotine (3). Coupling of 3 with 
ethyl acrylate followed by Sequential hydrogenation and 
ester hydrolysis will yield NH1. 
11 
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with NaBH, resolution with (+)-MTPA, and reductive 
debromination with hydrogen and palladium on carbon 
affords (S)-nor-nicotine (5). In yet another embodiment, 5 
can be obtained in an enantio-Selective Synthesis Starting 
with a chiral 2-hydroxy-3-pinanone ketimine. Treatment of 
5 with B-propiolactone in hot acetonitrile will afford NH2. 
SCHEME 2 
Br N - y 
21 N a, b, c 21 w 
N N 
N N 
2 
SCHEME 1. 
O 
B Br N Br - y 
21 OEt a, b 21 N c,d,e 21 w 
N N N CH 
N N N 
1. 2 
HOOC 
3 
EtOOC 
21 s g, h 21 
N 
N 
CH 
Key: (a) LiNCTMS)2, N-vinylpyrrollidinone; (b) MIC1, A; (c) NaBH4, CBZ-D-proline; (d) HCHO, HCOOH, A; (e) dibenzoyl-L-tartaric 
acid: (f) ethyl acrylate, Pd(OAc); PPh3. K2CO3: (g) H2, 10% Pd C: (h) methanesulfonic acid. 
0119). In yet another embodiment, NH1 may be prepared 
by first converting 3 to its iodo derivative, (S)-5-iodonico 
tine, via hexa-n-butylditin and a catalytic amount of tetraki 
S(triphenyl-phosphine)palladium followed by iodostannyla 
tion with iodine monochloride. In a further embodiment, 
NH1 can synthesized by producing (S)-5-ethylnicotine from 
3. This intermediate is then employed in a palladium cata 
lyzed coupling with ethyl chloroformate (52) to form the 
alkyne ester. AS described above, Sequential hydrogenation 
and ester hydrolysis of the alkyne ester yields NH1. 
0120 b. NH2: Carboxyl Modification of the Pyrrolidine 
Nitrogen of Nicotine. As shown in Scheme 2 below, the 
synthetic intermediate 2 described above will serve as the 
starting material for the synthesis of NH2. Reduction of 2 
CH 
N 
4 
-continued 
21 N 
s Nuco 
NH2 
Key: (a)NaBH4; (b) (+)-MTPA; (c) H2.10% Pd C; (d) B-propiolactone, A. 
0121. In still a further embodiment, the conversion of 5 
to NH2 is performed by conjugate addition of 5 to ethyl 
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acrylate followed by ester hydrolysis. Reductive alkylation 
of 5 with NaBH, and hydroxyacetic acid is another potential 
method to generate NH2. 
0122) c. NH3: Amino Modification of the Pyroline Ring 
of Nicotine. As shown in Scheme 3 below, synthesis of NH3 
may begin by treatment of the commercially available 
pyridine-3-carboxaldehyde with methylamine to form the 
imine. Treatment of the imine with Succinic anhydride in 
boiling xylene affords trans-1-methyl-4-carboxyl-5-(3-py 
ridyl)-2-pyrrolidone (7). Esterification and Subsequent 
lithium aluminum hydride (LAH) reduction affords trans 
3'-hydroxymethylnicotine (8). The final three steps in the 
synthesis of NH3; i.e., tosylation of alcohol 8, conversion to 
the azide, and azide reduction by LAH may be performed 
according to any generally known method. In yet another 
embodiment, NH3 may be formed by conversion of 7 to its 
4-carboxamide followed by an LAH reduction of both 
lactam and carboxamide functional groups. 
SCHEME 3 
HOOC 
O 
w 
Crs 21y O c, d -- -- 
N s CH 
6 7 
HO 
21 N 
N CH 
N 
8 
fg 
HN 
Key: (a) CH3NH2, 3 A molecular sieves: (b) succinic anhydride, A; (c) MeOH, 
H2SO4 (cat.); (d) LAH; (e) TosCl, Et3N: (f) NaN3, DMF, A; (g) LAH. 
0123 d. NH Characterization. The nicotine haptens NH1, 
NH2, and NH3, all reaction intermediates, and starting 
materials may be purified by distillation, crystallization, or 
flash column chromatography. These molecules may then be 
purified by analytical and semi-preparative HPLC and struc 
ture/composition confirmed by H and 'C NMR, infrared 
Spectroscopy, optical rotation, melting point, elemental 
analysis, and mass Spectrometry or any other generally 
known method. 
0.124. It will be appreciated by the skilled artisan that any 
number of variations for preparing the peptide or nicotine 
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hapten other than the methods set forth above may be 
utilized. In addition, it will also be appreciated by the is 
skilled artisan that methods other than those detailed above 
for attaching the nicotine hapten to the peptide may be 
employed. 
0.125 The following examples are provided to describe 
the invention in further detail. These examples are intended 
to illustrate the invention in greater detail. They are not 
intended to limit the invention in any way. 
EXAMPLE 1. 
Evaluation of Mucin Epitope (MUC1/C5a Agonist) 
Conjugate for Recruitment and Activation of 
Antigen Presenting Cells (APCs) and Stimulation 
of an Immune Response in Mice 
0.126 The C5a receptor is present on numerous antigen 
presenting cells, including monocytes, macrophages, den 
dritic cells, and other cell types. In this example, a composite 
peptide comprising a mucin epitope (MUC1) functionally 
linked to a decapeptide agonist analog of C5a corresponding 
to the C-terminal effector region of the natural favor was 
evaluated for its ability to activate the APCs thereby stimu 
lating an immune response in mice. This evaluation is based 
on the known property of C5a receptors to internalize and 
recycle in the antigen presenting cell, thereby acting as ideal 
candidates for delivering antigens to and Simultaneously 
activating Signals in the APCs. Because C5a receptors are 
particularly common on macrophages, monocytes and den 
dritic cells, it is believed that the use of a C5a agonist analog 
to bind C5a receptors will result in preferential activation of 
these APCs. 
0127 i. Abbreviations. Except where noted, the single 
letter designation for the amino acid residues is used: alanine 
is A, arginine is R; asparagine is N, aspartic acid is D; 
cystine is C; glutamine is Q; glutamic acid is E.; glycine is 
G; histidine is H, isoleucine is I; leucine is L.; lysine is K, 
methionine is M.; phenylalanine is F; proline is P; serine is 
S; threonine is T; tryptophan is W.; tyrosine is Y; and valine 
is V. Upper case letters represent the L-amino acid isomer 
and lower case the D-isomer. 
0128 ii. Peptide synthesis, Purification and Characteriza 
tion. The following peptides were Synthesized according to 
Standard Solid-phase methodologies on an Applied BioSys 
tems (Foster City, Calif.) model 430 A peptide synthesizer 
and characterized as previously described (7): 
0129 (1) The antigenic “juxta-membrane” (JM) 
epitope of the human mucin-1 (MUC1), YKQGG 
FLGL (SEQ ID NO:6): 
0130 (2) The C5a C-terminal decapeptide agonist 
analog, YSFKPMPLaR (SEQ ID NO:1); 
0131 (3) The composite peptide YKQGGFLGLYS 
FKPMPLaR (SEQ ID NO:2), in which the JM 
epitope is positioned toward the amino terminus and 
the C5a peptide is positioned toward the carboxyl 
terminus; and 
0132 (4) The composite peptide YSFKPM 
PLaRKQGGFLGL (SEQ ID NO:5), in which the JM 
epitope of MUC1 is positioned toward the carboxyl 
terminus and the C5a analog is positioned toward the 
amino terminus. 
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0.133 Peptide 3 retains C5a biological activity, whereas 
peptide 4 does not because the biologically important car 
boxyl terminal end of the C5a analog is blocked by the 
presence of the mucin epitope. AS Such, peptide 4 Serves as 
a control to determine the importance of the C5a biological 
activity to the effectiveness of these peptides for immuni 
Zation purposes. 
0134) Syntheses were performed on a 0.25 mmol scale on 
O-hydroxymethylphenoxymethyl polystyrene (HMP) resins 
(0.88 med/g Substitution). N'-amino groups were protected 
with the base-labile-9-fluorenylmethyloxycarbonyl (Fmoc) 
group. Side-chain functional groups were protected as fol 
lows: Arg (Pmc or 2,2,5,7,8-pentamethylchroman-6-sulfo 
nyl); Asp (Ot-butyl ester); Cys, Gln & His (Trt or trityl); Lys (Boc or t-butyloxycarbonyl); Ser & Tyr (t-butyl). Synthesis 
was initiated by the in Situ coupling of the C-terminal 
residue (N'-Fmoc-L-Arg(Prmc)) to the HMP resin in the 
presence of excess N-N'-dicyclohexylcarbodiimide (DCC) 
and 1-hydroxybenzotriazole (HOBT) with 4-dimethylami 
nopyridine (DMAP) as a coupling catalyst. Peptide chain 
elongation was accomplished by repetitive Fmoc deprotec 
tion in 50% piperidine in NMP followed by residue coupling 
in the presence of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetram 
ethyluronium hexafluorophosphate (HBTU). 
0135 Side-chain deprotection and cleavage from the 
resin were achieved in a single Step acetolysis reaction by 
Stirring the peptide-resin in a Solution of 84% trifluoroacetic 
acid (TFA), 6% phenol, 2% ethandithiol, 4% thioanisole, 
and 4% water for 1.5 hr at room temperature. Free peptide 
was precipitated from this Solution by adding cold diethyl 
ether. The mixture was filtered through a Scintered glass 
Buchner funnel (medium porosity) and the peptide/resin 
washed twice with cold ether to remove the thiol Scavenger. 
The peptide was extracted by Swirling the peptide/resin in 
the funnel with 20-30 ml aliquots of 10% acetic acid 
followed by filtration. The extraction aliquots were com 
bined, frozen and lyophilized to yield the powdered form of 
the crude peptide. 
0.136 Peptides were purified by preparative and analyti 
cal reverse-phase HPLC on columns packed with Cs 
bonded silica. The details of this procedure have been 
described by (4). All peptides were characterized by amino 
acid compositional analysis and fast atom bombardment 
mass spectrometry (FAB-MS). 
0.137 iii. Animal Models. The strains of mice used for 
this example were inbred females 6 to 12 week old 
C57Bl6(H-2) and Balb/c (H-2), which were obtained from 
Jackson labs (Bar Harbor, Me...). These two strains which 
differ in H-2 haplotypes, were used in this example to 
demonstrate that the observed antibody response were not a 
result of the Selection or creation of an unique immunogenic 
epitope characteristic of the Sequence of the proteins of the 
MHC class I and class II molecules important for antigen 
processing in one mouse Strain or another. The MUC1 
peptide Selected for these Studies contained a motif that may 
bind to the H-2K molecule of the C57B16 mice; therefore, 
a Strain of mouse that lacked this class I molecule binding 
motif (Balb/c) was also studied to determine the relative 
contribution of the class I binding motif to the antigen 
presentation properties of these peptides. 
0138 iv. Immunization protocol. Preimmune sera were 
obtained from mice, which were Subsequently immunized 
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intraperitoneally with 100 lug of the indicated peptide with 
RIBI adjuvant (MPL+TDM+CWS) (Sigma Immunochemi 
cals). Animals were boosted twice at two week intervals 
using the same injection procedure. Sera were obtained 
following three immunizations (at 6 weeks). 
0.139 v. Analysis of serum antibody responses. For radio 
immunoassay (RIA), anti-peptide antibodies were deter 
mined, before and at different time points after immuniza 
tion, in 96-well microtiter plates (Dynatech Laboratories, 
Inc.). Plates were coated with 50 ul of a 100 tug/ml appro 
priate peptide in phosphate-buffered saline (PBS) pH 7.4 
solution overnight at 4 C. The wells were blocked by 
incubation with 5% dry milk in PBS pH 7.4 for at least two 
hours. Anti-peptide antibody titers were determined using 
serial dilutions of Sera. The Sera were diluted with PBS 
containing 0.05% Tween-20, pH 7.4 (washing buffer) and 50 
All of each dilution was incubated at 37 C. for 1 hour. The 
wells were then drained, washed 4 times with PBS-Tween 
and 50 ul of 'I-goat anti-mouse Ab (1-2x10 cpm/well) 
was added and incubated for 1 hr at 25 C. After washing, 
Specific radioactivity was recorded in a gamma counter 
(1272 CliniGamma, LKB). 
0140 Anti-peptide antibody isotype titers were deter 
mined by enzyme-linked immunosorbent assay (ELISA) 
carried out in 96-well microtiter plates. The plates were 
coated with 100 tug/ml of appropriate peptide in PBS, pH 
7.4, and incubated overnight. The wells were blocked with 
5% dry milk in PBS pH 7.4 for at least two hours. Anti 
peptide titers were determined using Serial dilutions of Sera 
as described above. After the plates were washed 4 times, 50 
All of a 1:100 dilution of rabbit anti-mouse IgA, IgG1, IgG2a, 
IgG2b, IgG3 and IgM (Zymed) was added to each well and 
incubated at 25 C. for 1 hour. The plates were washed 4 
times with washing buffer and 50 ul of 1:500 goat anti-rabbit 
conjugated to peroxidase (Zymed) was incubated at 37 C. 
for 1 hour. Again, the plates were washed 4 times with 
washing buffer and bound enzyme was detected by the 
addition of 50 til 1 mg/ml p-nitrophenyl phosphate (Sigma) 
in 10% diethanolamine (Sigma) pH 9.4. The reaction was 
stopped by the addition of 50 ul of 0.5 M Sodium hydroxide 
and absorbance values (Alos) were determined on Titertek 
Multiskan (Flow Laboratories, Irvine, Scotland). 
0141 vi. Experimental groups. Experimental groups 
were as follows: 
0142 Group A. mice immunized with peptide (1) 
0143 Group B. mice immunized with peptide (2) 
0144) Group C. mice immunized with peptide (1) 
plus peptide (2) 
0145 Group D. mice immunized with peptide (3) 
0146 Group E. mice immunized with peptide (4). 
0147 The results of the experimental protocols are set 
forth in FIGS. 1 and 2. As can be seen in the Figures, the 
mice in Groups A, B, C and E produced no appreciable 
increase in antibody response to inoculation with MUC1 
epitope (Group A), C5a agonist peptide (Group B) MUC1 
epitope combined with, but not conjugated to, C5a agonist 
peptide (Group C), or MUC1 epitope conjugated to the C5a 
agonist peptide at its C-terminus, rather than its N-terminus (thereby blocking C5a biological activity) (Group E). Only 
mice inoculated with the MUC1 epitope/C5a agonist peptide 
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conjugate of the present invention (Group D) generated an 
appreciable antibody response. Furthermore, this stimula 
tion was significant. It is clear from these results that 
inoculation with the conjugated MUC1 epitope/C5a agonist 
peptide was far more efficient in Stimulating a general 
immune response (i.e., production of antibodies) than was 
inoculation with either peptide alone, or both peptides 
together, but not conjugated, or peptides conjugated in the 
opposite orientation. 
0.148. There are several significant conclusions that can 
be drawn based on these results. The fact that both Balb/c 
and C57B16 mice showed antibody responses to peptide 3 
Suggests that the antigen presenting effect is not restricted by 
MHC haplotype. The fact that immune responses were not 
produced to peptide 4, or to mixtures of peptide 1 and 2, but 
that Substantial responses were produced to peptide 3, Sug 
gest that the effect is mediated by the C5a moiety of the 
peptide and that the immune response results from the 
Simultaneous delivery of antigen peptide and C5a mediated 
activation signals to antigen presenting cells. 
014.9 The isotypes of the anti-peptide antibodies pro 
duced in the immunized mice were determined (FIG. 3) and 
were found to consist of IgM, IgG2a, and IgG2b. This 
Suggests that the immunogenic peptide is producing T 
cell-dependent responses, which generally require antigen 
processing and presentation. Data presented in FIG. 4 show 
that the antibody response to peptide 3 includes a high 
percentage of antibodies that are specific for the MUC1 
epitope that was antigen moiety of these Studies. 
EXAMPLE 2 
Evaluation of Serum Amyloid A/C5a Peptide 
Conjugates for Recruitment and Activation of APCs 
and Stimulation of Immune Response in Rats 
0150 Serum amyloid A is an acute-phase stress response 
protein generated by the liver. Along with other acute phase 
proteins, SAA is Secreted in response to Systemic inflam 
matory StreSS as a protective measure. SAA is of interest 
because it appears to be an excellent indicator of general, 
Systemic inflammation, which is a phenomenon that is very 
difficult to quantitate. Because serum levels of SAA have 
been observed to parallel the rise and fall of the systemic 
inflammatory response, quantization of Serum levels of this 
peptide would provide an effective means of assessing 
inflammation. One way to accomplish this is to develop 
antibodies against SAA that could be used for quantitation 
Such as in an ELISA assay. However, SAA has been par 
ticularly recalcitrant to the generation of antibodies against 
it. In this example, an evaluation was made of the ability of 
SAA conjugated to a C5a C-terminal analog (as described in 
Example 1) to activate antigen producing cells and produce 
an antibody response in rats. 
0151 i. Production and preparation of proteins and pep 
tides. The C-terminal C5a analog K-AhX-YSFKPMPLaR 
(SEQ ID NO:8) (AhX is aminohexanoic acid, which is a 
linear aliphatic spacer moiety) was produced as described in 
Example 1. The aliphatic Spacer moiety was included to 
Separate the critical receptor-binding C5a analog from the 
bulky protein to be attached to the amino terminus. 
0152 Serum amyloid A was conjugated to the C5a pep 
tide analogs according to the following method. SAA (100 
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pig) was reacted with a 50-fold molar excess of a water 
soluble carbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl 
carbodiimide methiodide (EDC), in 200 ul of phosphate 
buffered saline, pH 7.5, at room temperature for 30 minutes. 
A 50-fold molar excess of the peptide (K-Ahx-YSFKPM 
PLaR) (SEQID NO:8) and a 100-fold molar excess of a base 
diisopropylethylamine (DIEA) were added to this solution. 
Water was added to the solution to bring the reaction mixture 
to a volume of 400 ul. This solution was stirred overnight at 
room temperature and then lyophilized to a dry powder. The 
powder was diluted to the appropriate Volume with water to 
generate the Stock mixture used for inoculating the animals. 
0153 ii. Experimental protocols. Rats were injected 
intraperitonealy with an inoculant comprising the SAA/C5a 
peptide conjugates in phosphate-buffered Saline with or 
without RIBI adjuvant. Booster injections were given two 
and five weeks after the initial injections. The rats were 
Sacrificed Seven weeks after the initial injection and anti 
mucin antibody production was assessed from the Serum 
titers, as described in Example 1. 
0154) Significant anti-SAA antibody was produced from 
both groups of rats, whether or not RIBI adjuvant was 
included in the inoculation. AS Visualized by gel electro 
phoresis and autoradiography of anti-SAA antibody eluted 
from the plate assays, it appeared that anti-SAA antibody 
titers were essentially equivalent, or slightly higher, in rats 
inoculated with SAA/C5a peptide conjugate in the absence 
of RIBI adjuvant as compared to the same inoculation 
without the adjuvant. Thus, antigenic conjugates comprising 
the C5a peptide analog are useful for generating antibodies 
against large proteins, as well as against Smaller peptide 
fragments, Such as those described in Example 1. Moreover, 
the Successful generation of anti-SAA antibodies utilizing 
this method is particularly promising for purposes or pro 
ducing antibodies against weakly- or non-antigenic peptides 
or proteins. 
EXAMPLE 3 
Production and Characterization of Site-Directed 
Neutralizing Antibodies Specific for a Peptide 
(KR(33-52) from the Predicted Amino-Terminal 
Region of the Human Kappa Receptor 
O155 Receptors for human opioid peptide hormones 
have been described on numerous cell types. The receptors 
for u, K and 6 ligands have recently been cloned from 
genomic and cDNA libraries derived from normal tissue and 
cell lines. Considerable homology exists among the u, K and Ö receptors, except for the N-terminal regions of the recep 
tors. The N terminal region of the human kappa receptor 
(amino acid residues 1-100) is relatively hydrophilic and 
would be predicted to be exposed on the surface of the cell 
membrane. A 20 residue peptide KRG3-52)), was chosen 
and used to raise a Site directed peptide Specific polyclonal 
antibody (5). 
0156 The method of production of a polyclonal antise 
rum in rabbits using the molecular adjuvant, C5a-agonist 
peptide conjugated to the KR epitope is Set forth below. The 
binding Specificity and biological activities of the resulting 
polyclonal antiserum raised to the predicted extracellular 
region of the human kappa receptor (KR) are also described 
below. 
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O157 i. Construction of Targeted-Immunogen. A peptide 
construct consisting of the KR(33-52) (FPGWAEPDSNG 
SAGSEDAQL) (SEQ ID NO:9) covalently attached to the 
N-terminal end of a conformationally biased, C5a comple 
ment fragment agonist analogue peptide (YSFKPMPLaR) 
(SEQ ID NO: 1) was synthesized according to the methods 
in Example 1 and as previously reported (7). 
0158 ii. Preparation of anti-KR(33-52) Antiserum and 
Peptide-Specific ELISA. Rabbits were immunized s.c. with 
500 ug of FPGWAEPDSNGSAGSEDAQLYSFKPMLaR 
(SEQ ID NO:10) construct in complete Freund's adjuvant 
(GIBCO, Grand Island, N.Y.) on day 0 followed by booster 
injections on days 30 and 60 in incomplete Freund's adju 
vant. Serum was collected starting 75 days after the initial 
immunization. 
0159. The presence of anti-peptide antibody was deter 
mined by using a peptide Specific ELISA utilizing the free 
KR(33-52) peptide as previously described (8). Anti-KR(33 
52) and normal rabbit Y-globulin (RGG) were purified by 
protein A Sepharose chromatography (Sigma) (8) prior to 
Sc. 
0160 iii. Cells and culture conditions. The neuroblas 
toma cell SK-N-SH (HTB 11), ductal breast cell carcinoma 
T47D (HTB 133), Jurkat T cell leukemia, (TIB 152), U937 
histolytic lymphoma (CRL1593), THP1 human monocyte 
(TIB 202), EBV-transformed B cells SKW 6.4 (TIB 215) 
and CESS (TIB 190) (American Type Culture Collection, 
Rockville, Md.) were cultured in DMEM or RPMI 1640 
supplemented with 10% fetal calf serum, 25 mM HEPES, 1 
mM L-glutamine, 2 mM Napyruvate, 50 Upenicillin and 50 
tug/ml Streptomycin. The human neuronal precursor cells 
NT2 (Stratagene, La Jolla, Calif.) were cultured in Opti 
MEM (Gibco) supplemented as above. All cultures were 
incubated at 37° C. in a humidified chamber with 7.5% CO. 
0.161 Peripheral blood derived mononuclear cells were 
obtained from healthy male and female Volunteers, isolated 
by Ficoll-Hypague" density gradient centrifugation and 
enriched for macrophage by adherence to plastic. 
0162 iv. Flow Cytometry. Single-color flow cytometry 
analysis of cells (1x10") in PBS containing 1% bovine calf 
Serum and 0.1% Sodium azide (staining buffer) were prein 
cubated 30 minutes at 4 C. in the presence of 20% normal 
human serum. The cells were washed and incubated with 
anti-KR(33-52) or RGG for 30 minutes at 4 C., washed and 
labeled with PI-conjugated donkey (Fab") fragments of 
antirabbit IgG (Zymed, S. San Francisco, Calif.) for 30 
minutes at 4 C. (8). For dual color analysis FITC-conju 
gated anti-CD3 or anti-CD14 (Pharmingen, San Diego, 
Calif.) were also included in the second step. Cells (1x10") 
were analyzed on a FACScan (Becton Dickinson, Mountain 
View, Calif.) and data were analyzed with the Cell Quest 
software as previously described (8). 
0163 v. Measurement of cell proliferation. Peripheral 
blood mononuclear cell (PBMC) were pulsed on day 2 of 
culture with H-thymidine and 18 hours later the cells 
harvested on glass fiber filters and processed for Scintillation 
counting. Experiments were performed three times and each 
Sample done in triplicate. 
0164 vi. Measurement of IgG Secretion. Relative IgG 
levels in culture Supernatants were determined by indirect 
ELISA as previously described (9). Supernatant derived 
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from PBMC cultures were collected after 10 days and 
assayed for the presence of IgG. Numbers represent the 
mean CPM+/-SD from triplicate samples. Experiments 
were performed at least three times. 
0.165 vii. Characterization of Anti KR Peptide Antiserum. 
Serum from rabbits immunized with the KR(33-52) YSFP 
MPLaR (SEQ ID NO:10) construct and normal rabbit serum 
were assayed for the ability to recognize plate bound KR(33 
52) (SEQ ID NO:9) in ELISA. The results show that serum 
from rabbits immunized with the KR(33-52) YSFPMPLaR 
(SEQ ID NO:10) construct bound free KR(33-52) peptide 
(SEQ ID NO:9) in a dose dependent fashion. The titer was 
approximately 105. In contrast, Serum from unimmunized 
rabbits failed to bind this peptide. Serum samples from 
immunized and unimmunized rabbits were Subjected to 
protein A-Sepharose chromatography and the column elu 
ates were assessed for KR(33-52) (SEQ ID NO:9) specific 
antibody. The results indicate that protein A-purified anti 
body derived from rabbits immunized with the KRG3-52) 
YSFPMPLaR (SEQ ID NO:10) construct binding to free 
KR(33-52) (SEQ ID NO:9) was detectable at antibody 
concentrations less than 0.1 ng/ml. In contrast, RGG failed 
to bind the free peptide. The results from multiple bleedings 
indicated that the EDso titer ranged between 1-10 ng/ml. 
These results indicate that rabbits immunized with KR(33 
52) YSFPMPLaR (SEQ ID NO:10) contained high titer, 
KR(33-52) peptide specific antibody. 
0166 viii. Binding of anti-R (33-52) antibody to cells 
expressing human KR. To determine whether the polyclonal 
anti-KR(33-52) antibodies bound to cells expressing the KR, 
a variety of mononuclear cells lines and normal human 
mononuclear cells were first assayed for the presence of the 
K receptor specific mRNA by RT-PCR. RNA samples iso 
lated from neuronal cell lines NT2, U937, Jurkat, T47D, 
normal human PBMC, and enriched human macrophage 
were subjected to RT-PCR analysis with 5' sense and 3' 
antisense primerS Specific for the 3' region of the cloned KR 
and B-actin. All of the cell lines or cell fractions, except for 
the T47D cell line, were positive for the K-receptor specific 
PCR product, as expected based on the primer Sequences 
used (5). 
0.167 Experiments were performed to determine whether 
anti-KR(33-52) bound to cells expressing KR specific 
mRNA. The results of single color flow cytometric analysis 
for several cell lines are shown in Table 2. Flow cytometric 
measurements were conducted with human cell lines repre 
sentative of macrophage (U937), T lymphocytes (Jurkat), 
and B lymphocytes (SKW 6.4 and CESS). The results 
indicate that anti-KR(33-52) bound all three cell types. 
Anti-KR(33-52) bound to U937 cells to the greatest extent 
(MFI-231) compared to normal RGG (MFI-38). As used 
herein MFI refers to mean fluorescence intensity. Compari 
son of anti-KR(33-52) and RGG binding to the Jurkat line 
indicated approximately a 3-fold shift in MFI (MFI =18 vs. 
MFI=6). Similar results were obtained with the two B 
lymphocyte-like cell lines (SKW 6.4 and CESS). Compari 
son of anti-KR(33-52) and RGG binding to the SKW 6.4 line 
indicated approximately a 3-fold shift in MFI (MFI =19 vs. 
MFI=6). The neuronal cell line was also specifically bound 
by the anti-KR(33-52) as indicated by a 3-fold shift in the 
MFI over the RGG. Finally, based on the lack of expression 
of KR-specific mRNA from the human breast carcinoma cell 
line (T47D), this cell line was assessed for its ability to bind 
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to anti-KR(33-52) by flow cytometric analysis. The lack of 
a KR expression on T47D cells was confirmed by the fact 
that anti-KR(33-52) and RGG bound to these cells in an 
almost identical fashion. As a positive control, anti-KR(33 
52) and RGG were assessed for their ability to bind to an 
additional human macrophage-like cell line (THP1). Com 
parison of anti-KR(33-52) and RGG binding to this cell line 
resulted in a significant shift in MFI (MFI-190 vs. MFI=8). 
These results confirm the specificity of anti-KR(33-52) for 
the human KR. 
TABLE 1. 
Selected cell type binding of anti-KR(33-52) 
antibodies produced in rabbits immunized with C5a-agonist 
peptide conjugated to the KRG33-52) sequence as assessed 
by single channel color flow cytometric analysis. 
Mean Channel Intensity 
Cell Line Cell Type RGG anti-KR Ab 
NT2 Neuronal 9 19 
U937 Macrophage 38 231 
Jurkat T-lymphocyte 6 18 
SKW 6.4 B-lymphocyte 6 19 
CESS &10 &10 
Controls Human breast -3 -3 
T47D (negative) Carcinoma 
THP1 (positive) Macrophage 8 190 
0168 Analysis of intact human PBMC indicated that 
these cells express mRNA for a “K-like" R (5). Dual color 
flow cytometric analysis was utilized to assay for the bind 
ing of anti-KR(33-52) to normal human macrophage 
(CD14+) and T lymphocytes (CD3+). It was observed that 
both macrophage and T lymphocytes bound anti-KR(33-52) 
antibody. Anti-KR(33-52) and RGG were assessed for bind 
ing to CD14+ PBMC. The results indicate that anti-KR(33 
52) bound CD14+ cells with a 15-fold increase compared to 
normal RGG (MFI-320 vs. MFI=21). Anti-KR(33-52) was 
also found to bind CD3+ cells (MFI-19 vs. RGG MFI=3) 
albeit less than CD14+ cells. These results indicate that 
anti-KR(33-52) binds normal PBMC-derived mononuclear 
cells as well as mononuclear cell lines, which express 
KR-specific mRNA. 
0169 ix. Neutralization of U50,488H-mediated Suppres 
sion of lymphocyte proliferation by anti-KR(32-52) antibody 
in vitro. The results of published studies have shown that 
opioid peptide-induced regulation of in Vitro immune 
responses can occur via Specific receptor-ligand interactions. 
More specifically, it has been shown that the KR-selective 
agonist U50,488H is capable of suppressing SAC-induced 
lymphocyte proliferation by human PBMC cultures (6). The 
inhibition of lymphocyte activation by U50,488H has also 
been shown to be reversed by the KR-Selective antagonist 
nor-BNI. To determine whether anti-KR(33-52) was capable 
of acting as an KR Selective antagonist and neutralizing 
U50,488H-mediated Suppression, PBMC cultures were pre 
incubated with various concentrations of protein A purified 
anti-KR(32-52) prior the addition of SAC and U50,488H. 
U50,488H Suppresses SAC-induced lymphocyte prolifera 
tion in a dose dependent fashion (5). Maximal Suppression 
was obtained when U50,488H was used at a concentration 
of 10 M. PBMC cultures were preincubated with various 
concentrations of anti-KR(33-52) (1-50 ug/ml), followed by 
the addition of U50,488H plus SAC, and proliferation 
measured on day 3 of culture. Anti-KR(33-55) was found to 
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neutralize U50,488H-mediated suppression of SAC-induced 
lymphocyte proliferation in a dose dependent fashion. In 
contrast, identical concentrations of normal RGG failed to 
inhibit KR Selective agonist mediated immunosuppression. 
0170 Since SAC has been shown to induce both Tand B 
lymphocyte proliferation, Similar experiments were con 
ducted with the T cell mitogen PHA. Anti-KR(33-52) was 
also able to neutralize the ability of U50,488H to suppress 
mitogen-induced T cell proliferation. U50,488H (10 M) 
suppressed PHA-induced T cell proliferation by 85%. This 
Suppression was reversed by preincubating the cells with 
anti-KR(33-52). Preincubation of PBMC with normal RGG 
failed to block U50,488H-mediated suppression of T cell 
proliferation. 
0171 Anti-KR(33-52) does not appear to directly modu 
late lymphocyte proliferation. The co-culture of PBMC with 
anti-KR(33-52), in the absence of mitogen, failed to stimu 
late the cells above the media control. Moreover, the com 
bination of anti-KR(33-52) and PHA or SAC did not result 
in increased cell proliferation compared to PBMC cultures 
receiving mitogen only. 
0172 X. Neutralization of U50,488N-mediated suppres 
sion of IgG synthesis by anti-KR(32-52) antibody in vitro. In 
addition to lymphocyte proliferation, U50,488H is a potent 
inhibitor of SAC-induced IgG synthesis in human PBMC 
cultures (6). To determine whether anti-KR(32-52) was 
capable of neutralizing the Suppression of IgG Synthesis, 
PBMC were preincubated with anti-KR(32-52) followed by 
the addition of U50,488H and SAC, and IgG levels mea 
sured on day 10. Results indicate that U50,488H at 10 M 
and 107 M inhibited IgG synthesis by 67% and 85% 
respectively (5). The inclusion of anti-KR(32-52) in culture 
was found to neutralize Suppression of SAC induced IgG 
Synthesis in a dose dependent manner. In contrast, Similar 
concentrations of normal RGG failed to neutralize the 
observed Suppression. 
0173 To assess the specificity of anti-KR(32-52) anti 
body, PBMC were incubated with specific antibody or RGG 
followed by co-culture with U50,488H or the u receptor 
Selective agonist (DAGO) and IgG production measured by 
ELISA. The results indicate that, whereas, anti-KR(32-52) 
neutralized U50,488H-mediated inhibition of SAC-induced 
IgG synthesis, anti-KR(32-52) was unable to neutralize 
DAGO-mediated Suppression of IgG Synthesis. 
0.174. These results indicate that in addition to binding 
lymphocytes and macrophage, anti-KR(32-52) is capable of 
neutralizing the ability of a KR selective agonist (U50, 
488H), but not auR selective agonist (DAGO). Additionally 
the antibody demonstrated significant inhibition of both 
lymphocyte proliferation and differentiation to antibody 
Synthesis. These results further demonstrate the Specificity 
of anti-KR(33-52) for the human kappa receptor. 
0.175 AS can be seen from the antibody binding data 
presented above, the Site directed polyclonal antibodies 
raised in rabbits using the C5a-agonist form of the molecular 
adjuvant conjugated to the K receptor Sequence were capable 
of binding to normal human cells and cell lines expressing 
mRNA specific for the human K receptor. Flow cytometric 
analysis of a neuronal cell line (NT2), normal blood-derived 
CD14+monocytes, monocyte-like cell lines (U937 and 
THP1), normal blood derived CD3+ T cells and a T cell line 
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(Jurkat), and human B cell lines (SKW6.4 and CESS) 
revealed that the cells were all bound by anti-KR(33-52) in 
a specific manner. The anti-KR(33-52) did not bind to a cell 
line determined not to express mRNA for the human K 
receptor. 
0176 Anti-KR(32-52) was found to specifically neutral 
ize KR-selective agonist (U50,488H)-mediated inhibition of 
lymphocyte activation. The antiserum was found to neutral 
ize, in a dose dependent manner, U50,488H-mediated inhi 
bition of: 1) SAC-induced lymphocyte proliferation; 2) 
PHA-induced lymphocyte proliferation and; 3) SAC-in 
duced IgG Synthesis. In contrast, DAGO-mediated Suppres 
sion of SAC-induced IgG production was not affected by 
anti-KR(32-52). These results suggest that this site directed 
polyclonal antiserum Specifically interacts with the human 
KR on PBMC. The results presented indicate that polyclonal 
anti-KR(32-52) antibodies interact with the exposed N-ter 
minal region of the KR. While this antiserum effectively 
blocked U50,488H-mediated lymphocyte activation, it did 
not activate macrophage or lymphocytes. 
0177. While anti-Kopioid receptor antibodies are exem 
plified above, conjugation of C5a agonist peptide to peptides 
corresponding to p and Aspecific peptides has resulted in the 
Successful generation of Specific antibodies to the p and A 
epitopes. 
EXAMPLE 4 
Comparison of Immunogenicity of Epitope-C5a 
Agonist Constructs with Epitope-KLH Conjugates 
0.178 The following experiment was performed in order 
to compare the potency of the molecular adjuvant of the 
present invention with a widely used method for enhancing 
the immune response to peptide epitopes. The objective was 
a direct comparison of the response to a construct of MUC1 
epitope-C5a agonist and the same epitope conjugated to 
keyhole limpet hemocyanine (KLH) in mice. The results are 
Summarized in Table 2. 
TABLE 2 
MUC1 Specific Ab Isotype Titers Produced with Different Immunogens. 
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0181 Five C57BL6 were immunized and boosted with 
YKQGGFLGL-KLH (SEQ ID NO:6-KLH) and sera were 
obtained as indicated in the Materials and Methods section. 
Standard error of responder titer values was less then 25% 
for IgM and less than 40% for IgG1. 
0182. A similar experiment was performed in rabbits. 
The immunogens used in rabbits were the K- and u-opioid 
receptor epitopes, FPGWAEPDSNGSAGSEDAQL (SEQ 
ID NO:9) and GDLSDPCGNRTNLGGRDSL (SEQ ID 
No:11), respectively. The serum antibody titer and antibody 
Subtypes produced in rabbits injected with the two compo 
Sitions containing the different immunogens were compared. 
0183) i. Peptide conjugates. In one instance the epitopes 
were conjugated to KLH Via a lysine residue added Syn 
thetically to the N-terminus of the epitope along with an 
alanine residue which acted as a Spacer. In this experiment, 
glutaldehyde was used to effect conjugation. In the another 
case, the epitopes were linked to the N-terminal end of the 
C5a agonist YSFKPMPLaR (SEQ ID NO:1) using the solid 
phase peptide Synthetic methodologies described above in 
example 1. 
0.184 ii. Immunization protocol for rabbits. Rabbits were 
immunized s.c. with 500 lug of either the epitope-KLH or the 
epitope-YSFKPMPLaR (epitope-SEQ ID NO:1) constructs 
in compete Freund's adjuvant (GIBCO, Grand Island, N.Y.). 
Booster injections were administered on days 30 and 60 in 
incomplete Freunds's adjuvant. Serum was collected Start 
ing at day 60 post-immunization. 
0185. iii. Antibody determination. The presence of rabbit 
IgG Specific for the peptide epitopes was determined by 
ELISA as previously described (8). Rabbits immunized with 
the epitope-C5a agonist generated high titer IgG AbS Spe 
cific for the opioid receptor peptide epitopes. The rabbits 
immunized with the opioid receptor epitopes conjugated to 
the carrier protein KLH also produced high titer antibodies 
Specific epitopes to which they were injected. These results 
demonstrate that the decapeptide C5a-agonist was as effec 
Ab IsotVDes and Titers' 
IgA IgG1 IgG2a IgG2b IgG3 IgM 
YKOGGFLGLYSFKPM O O 1260 1780 (5/5) 0 (5/5) 6310 (5/5) 
PLaRP 
(SEQ ID NO: 2) 
YKOGGFLGL-KLHe O 100 (2/5) O O O 5010 (4/5) 
(SEQ ID NO: 6-KLH) 
0179 Sera were screened against MUC1 peptide and 
mean titer values of responders are shown. Parentheses 
indicate the number of responders. Ab titer is defined as the 
Sera dilution within the linear range at which specific 
reactivity is lost. 
0180 Five C57BL6 mice were immunized and boosted 
with YKQGGFLGLYSKFPMPLaR (SEQ ID NO:2) and 
Sera were obtained as indicated in the Material and Methods 
Section. Standard error of responder titer values was leSS 
than 32% for all isotypes. 
tive as the large molecular weight protein, KLH, conjugated 
to the epitope at inducing Specific anti-peptide antibodies in 
non-rodent species. 
EXAMPLE 5 
Evaluation of C5a Peptide to Function as a 
Molecular Adjuvant and Epitope Delivery System 
for a Defined CTL Epitope of Hepatitis B Virus 
Surface Antigen 
0186 Experiments were performed in which YSFKPM 
PLaR (SEQID NO: 1) was used as a molecular adjuvant for 
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inducing antigen-Specific CTL responses against a defined 
CTL peptide epitope from the hepatitis B Surface antigen 
(HBSAg). The HBSAg CTL epitope was covalently attached 
to either the N-terminus of YSFKPMPLaR (SEQ ID NO: 1) 
(C5a-active constructs) or to its C-terminus (C5a-inactive 
constructs). Mice were immunized with these C5a-active 
and C5a-inactive constructs in the absence of any added 
adjuvant in order to evaluate the ability of YSFKPMPLaR 
(SEQ ID NO: 1) to provide the necessary signals and/or 
targeting required for the induction of an antigen-Specific 
CTL response. Immunizations were also performed with 
C5a-active constructs containing protease-Sensitive linker 
sequences between the HBSAg CTL epitope and the C5a 
agonist. The results of these experiments were analyzed in 
terms of a possible mechanism by which YSFKPMPLaR 
(SEQID NO: 1) induces antigen-specific CTL responses and 
the importance of a protease-Sensitive Sequence between the 
epitope and the C5a agonist. 
0187 Materials and Methods: 
0188 Peptide synthesis. Peptides were synthesized by 
Standard Solid phase methodologies on an Applied BioSys 
tems (Foster City, Calif.) model 430Asynthesizer. Syntheses 
were performed on a 0.25-mmol Scale and employed the 
Fmoc (9-fluorenylmethyloxycarbonyl)method of repetitive 
residue linkages. Peptide purification was accomplished 
with analytical and preparative HPLC on columns packed 
with Cs bonded Silica. All peptides were characterized by 
amino acid compositional analysis and mass Spectrometry. 
The details of these methods of Synthesis, purification, and 
characterization have been described previously (Sanderson 
et al., J. Med. Chem. 37, 3171, 1994). 
0189 Pharmacologic assays. C5a-like agonistic activity 
was assessed by the ability of the peptides to induce Smooth 
muscle contraction of human umbilical artery and i release 
from human PMNs according to previously published meth 
ods (Sanderson et al., 1994, Supra; Sanderson et al., J. Med. 
Chem. 38, 3669, 1995; Finch et al., J. Med. Chem. 40,877, 
1997). Full concentration-response curves were generated 
for individual peptides and natural C5a in each assay and the 
ECso values (the concentration of peptide producing 50% of 
the maximal response to each peptide) were calculated. pl.) 
transforms -log ECso (M) were calculated for each con 
centration-response curve and reported as the meantSE. 
Peptide binding affinity to the C5aR was evaluated on intact 
human PMNs by a competition assay using 'I-C5a accord 
ing to previously described methods (Sanderson et al., 1995, 
supra; Finch et al., 1997, Supra). Statistical analysis of the 
values obtained from pharmacologic assays was performed 
using one-way analysis of variance (ANOVA). 
0190 Animals. Female BALB/c (H-2) mice 10 to 12 
weeks old were purchased from the Jackson Laboratory (Bar 
Harbor, Me...). On arrival, mice were housed in isolator 
cages, provided autoclaved food and water ad libitum, and 
quarantined for Seven days. On release from quarantine, the 
mice were entered into the Study following written protocols 
on file with the Animal Care and Use Committee and in 
compliance with the Animal Welfare Regulations (9CFR). 
0191 Immunization protocols. Groups of six to eight 
BALB/c mice were given bilateral S.c. injections in the 
inguinal area with (100 ul each side) of a PBS solution 
containing 50-100 ug of the peptides. Booster injections 
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were given S.c. in the inguinal region at 21-day intervals. 
Sera for Ab analysis were obtained by retro-orbital bleeds of 
mice under CO2 narcosis. 
0.192 Spleen cell cultures and in vitro stimulation. Three 
weeks after Secondary (2) immunization and two weeks 
after tertiary (3) immunization, two to three mice from each 
experimental group were Sacrificed by cervical dislocation 
and their spleens removed aseptically. Pooled Splenic Single 
cell suspensions were prepared in RPMI-1640 medium 
(Sigma, St. Louis, Mo.) containing 10% FBS (Hyclone, Salt 
Lake City, Utah) and the following supplements: 10 mM 
HEPES buffer, 50 uM 2-ME, 2 mM L-glutamine, 50 lug/ml 
gentamicin Sulfate, 100 U/ml penicillin, and 50 lug/ml Strep 
tomycin (all Supplements from Sigma). This Supplemented 
complete medium is designated RP10-SC. For culture, 
75x10 pooled spleen cells in 5 ml of RP10-SC were pipetted 
into a 25 cm^ T-flask (Corning). Next, 5 ml of RP10-SC 
containing 150 nM of synthetic, L' MHC class I-restricted 
peptide, IPQSLDSWWTSL (SEQ ID NO:12) were added to 
the flask. The flasks were incubated undisturbed in an 
upright position at 37 C. in 5% CO. After 4 days of 
incubation, the cells were recovered from the T-flasks, 
washed, once by centrifugation in fresh RP10-SC, resus 
pended in 5 ml RP10-SC, counted, and adjusted to 5x10° 
viable cells/ml. 
0193 Target cell lines. The specific cell target used for 
measuring CTL activity was P815S, a transfectant cell line 
of P815 (H-2) expressing the HBSAg (14). P815S was 
grown in RP10-SC medium containing 400 tug/ml geneticin 
disulfate (G418, Sigma). The parental H-2' mastocytoma 
cell line, P815 (ATTC #TIB64) grown in RP10-SC medium, 
was used as a non-specific target for CTL assays to measure 
% non-Specific lysis. In all the experiments shown, this 
value was less than 5% at effector-to-target ratios of 50:1. 
0194 Target cell labeling. The target cells, either P815S 
O P815, were washed 2 times in RP10-SC. For labeling, 
5x10 target cells were mixed with 250 uCi Cr-sodium 
chromate 400-1200 Ci (14.8-44.4 TBq)/g; NEN Dupont, 
Boston, Mass.) in a 1.0 ml volume in a 50 ml conical tube 
and incubated in a 37 C. water bath for 90 minutes. After 
incubation, the labeled cells were washed 3 times by cen 
trifugation using 15 ml volumes of fresh RP10-SC and 
allowed to stand at room temperature for 30 minutes. The 
pelleted cells were resuspended in RP10-SC at 1x10 cells/ 
ml. 
0.195 Cytotoxicity assay. The recovered splenic effector 
cells at 5x10 cells/ml were serially diluted in triplicate in 
wells of round-bottom 96 well plates (Corning, 25850) in a 
total volume of 100 ul/well and using RP10-SC as the 
diluent. Next, 100 ul volumes of Cr-labeled targets, P815S 
or P815, at 1x10 cells/ml were added to the wells. Maxi 
mum release (MR) wells contained 100 ul of target cells and 
100 ul of 2% (v/v) Tween 20 while spontaneous release (SR) 
wells contained labeled cells in medium alone. Effector-to 
target ratios of 50:1, 25:1, 12.5:1, and 6.25:1 were routinely 
employed. The plates were centrifuged at 400xg and incu 
bated at 37° C. in 5% CO for 4 hrs. After incubation, the 
Supernatant fractions in the Wells were collected using a 
Skatron Supernatant Collection System (Skatron Instru 
ments, Sterlin, Va.). The amount of Cr radioactivity in the 
Supernatant fractions was measured using a Wallac 1470 
Wizard gamma counter (Turku, Finland). Percent specific 
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lysis was calculated as (experimental release-SR/(MR 
SR)x100. The SR was always less than 10% of the MR. All 
assays were performed in triplicate. 
0196) Results: 
0197) Peptide design. Peptide immunogens were 
designed to evaluate the requirement for C5a agonist activity 
in the induction of Antigen-Specific CTL responses. C5a 
active constructs were generated by the covalent attachment 
of the HBSAg CTL epitope to the N-terminus of the C5a 
agonist: IPQSLDSWWTSLYSFKPMPLaR (SEQ ID NO: 
13) IPQSLDSWWTSLRRYSFKPMPLaR (SEQ ID NO: 
14), and IPQSLDSWWTSLRVRRYSFKPMPLaR (SEQ ID 
NO: 15). This positioning of the CTL epitope relative to the 
C5a agonist leaves the biologically important conforma 
tional features expressed in the C-terminal region of 
YSFKPMPLaR (SEQID NO: 1) free to interact with C5aRs 
expressed on the cells involved in antigen uptake and 
processing. The latter two peptides were designed to evalu 
ate if predicted protease-Sensitive linker Sequences placed 
between the HBSAg CTL epitope and the C5a agonist might 
facilitate intracellular release of the epitope into antigen 
presenting pathways and thereby enhance the response. The 
linkers consisted of a dibasic double-Arg (RR) Sequence, 
which is Susceptible to cleavage by proteases of the Subtili 
Sin family and trypsin-like proteases. The other was a 
Sequence Sensitive to the ubiquitous intracellular Subtilisin 
like protease furin, RVRR (SEQ ID NO: 19). This latter 
Sequence is found at the junction of the A and B fragments 
of diphtheria toxin (DT) and it is believed that furin plays a 
prominent role in the intracellular proteolytic activation of 
DT and several other bacterial toxins as well as in the 
processing of proproteins and prohormones that contain the 
consensus sequence RX(K/R)R. C5a-inactive constructs 
were generated by blocking the functionally important car 
boxyl group on the C-terminal Arg of YSFKPMPLaR (SEQ 
ID NO:1) with either the HBSAg CTL epitope, YSFKPM 
PLaRRRIPQSLDSWWTSL (SEQID NO: 16) or with a Gly 
residue, IPQSLDSWWTSLRRYSFKPMPLaRG (SEQ ID 
NO: 17). 
0198 Pharmacologic activities. All peptides were evalu 
ated for C5a agonist activities in assays that measured 
peptide-mediated contraction of Smooth muscle in human 
umbilical artery (Table 3), the release of MPO from human 
PMNs (Table 4), and binding to C5aRs expressed on the 
surface of human PMNS (Table 5). Constructs in which the 
HBSAg CTL epitope was attached to the N-terminus of the 
C5a agonist, IPQSLDSWWTSLYSFKPMPLaR (SEQ ID 
NO: 13), IPOSLDSWWTSLRRYSFKPMPLaR (SEQ ID 
NO: 14), and IPQSLDSWWTSLRVRRYSFKPMPLaR 
(SEQ ID NO: 15) behaved as full agonists relative to natural 
C5a with potencies and C5aR binding affinities comparable 
to or greater than YSFKPMPLaR (SEQ ID NO: 1). In 
contrast, the construct in which the functionally important 
C-terminal carboxyl group of the C5a agonist moiety was 
blocked with the HBSAg CTL epitope YSFKPMPLaR 
RRIPQSLDSWWTSL (SEQ ID NO: 16) was significantly 
less potent in umbilical artery contraction (Table 3), inactive 
in MPO release from PMNs (Table 2), and bound poorly to 
the C5aR (Table 5) relative to both natural C5a and YSFKP 
MPLaR (SEQ ID NO: 1). Similarly, the construct in which 
a Gly residue blocked the C-terminal carboxyl group of the 
agonist moiety IPOSLDSWWTSLRRYSFKPMPLaRG 
(SEQ ID NO: 17) was significantly less potent than its 
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C5a-active counterparts in umbilical artery contraction 
(Table 3) and bound with significantly less affinity to the 
C5aR (Table 5). This construct was unable to induce a full 
response relative to natural C5a in MPO release from PMNs (Table 4). CTL responses are induced in mice when the L' 
MHC class I restricted peptide, Sso, of HBSAg is 
covalently attached to the N-terminus of the C5a agonist via 
an Arg-Arg linkage. Initial experiments were designed to 
evaluate CTL induction by the free L' MHC class I-re 
stricted peptide Ss, IPQSLDSWWTSL (SEQ ID NO: 
12), the same peptide with two Arg residues added to the 
C-terminus, IPQSLDSWWTSLRR (SEQ ID NO: 18), the 
free C5a agonist, YSFKPMPLaR (SEQ ID NO: 1) and 
admixtures of the above peptides. Of particular interest was 
the evaluation of C5a-active constructs in which the HBSAg 
CTL epitope was covalently attached either directly to the 
N-terminus of the C5a agonist IPOSLDSWWTSLYSFKP 
MPLaR (SEQ ID NO: 13) or through the double-Arg, 
protease-sensitive linker IPOSLDSWWTSLRRYSFKPM 
PLaR (SEQ ID NO: 14). The administered amounts of the 
latter two constructs were adjusted to reflect amounts equal 
(by weight) to that of the free HBSAg CTL epitope based on 
relative molecular mass. Mice in each group received two 
injections, Spaced 21 days apart, of the indicated construct. 
Mice in each group were tested for Splenic CTL activity at 
day 42 as described in Materials and Methods. As shown in 
Table 6, only the group injected with the double-Arg-linked 
construct IPQSLDSWWTSLRRYSFKPMPLaR (SEQ ID 
NO: 14) exhibited a significant CTL response against the 
P815S transfected target cells. 
0199 C5a agonist activity is necessary for the induction 
of antigen-specific CTL responses. To evaluate the necessity 
of C5a agonist activity in the induction of antigen-specific 
CTL responses, mice were immunized with C5a-active and 
C5a-inactive HBSAg CTL epitope-containing constructs. 
C5a-active constructs were generated by the covalent attach 
ment, via the protease-Sensitive, double-Arg linker 
sequence, of the HBSAG CTL epitope to the N-terminus of 
the C5a agonist IPOSLDSWWTSLRRYSFKPMPLaR 
(SEQ ID NO: 14). C5a-inactive constructs were generated 
by blocking the functionally important carboxyl group on 
the C-terminal Arg of the C5a agonist with either the HBSAg 
YSFKPMPLaRRRIPQSLDSWWTSL (SEQ ID NO:16) or a 
Gly residue IPQSLDSWWTSLRRYSFKPMPLaRG (SEQ 
ID NO: 17). The double-Arg-containing HBSAg CTL 
epitope IPQSLDSWWTSLRR (SEQ ID NO: 18) was used 
as a control. AS shown in FIG. 1, only mice that were 
immunized with the C5a-active construct IPOSLDSW 
WTSLRRYSFKPMPLaR (SEQ ID NO:14) generated an 
antigen-specific CTL response. The phenotype of the effec 
tor cells responsible for the in vitro cytolytic activity in these 
experiments was determined to be CD8+ as judged by the 
ability of a rat anti-mouse lyt 2.2 MAb (2.43, ATCC TIB 
210) to almost completely inhibit (greater than 90% inhibi 
tion) the cytolytic process. In contrast, a rat anti-mouse 
L3T4 monoclonal antibody (GK1.5, ATCC TIB-207) known 
to block CD4 T cell activity had no effect on the in vitro 
cytolysis induced by the active constructs (data not shown). 
0200 CTL responses are induced only by C5a-active 
constructs containing a protease-Sensitive linker Sequence 
between epitope and C5a agonist. To evaluate the require 
ment for a protease-Sensitive linkage between the HBSAg 
CTL epitope and the C5a agonist for CTL induction, mice 
were immunized with C5a-active constructs in which the 
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HBSAg CTL epitope was covalently attached directly to the 
N-terminus of the C5a agonist IPOSLDSWWTSLYSFKP 
MPLaR (SEQ ID NO: 13) or separated by protease-sensitive 
linker sequences IPOSLDSWWTSLRRYSFKPMPLaR 
(SEQ ID NO: 14) and IPQSLDSWWTSLRVRRYSFKPM 
PLaR (SEQ ID NO: 15). As noted previously, the double 
Arg (RR) Sequence is sensitive to cleavage by proteases of 
the Subtilisin family and other trypsin-like proteases. The 
RVRR (SEQ ID NO: 19) sequence is a motif recognized by 
the intracellular protease furin. The results shown in FIG. 2 
indicate that of the three C5a-active constructs, only those 
containing the protease-Sensitive linker Sequence between 
the HBSAg CTL epitope and the C5a agonist were capable 
of inducing an antigen-Specific CTL response in mice. 
Although the RVRR-containing construct was able to elicit 
a specific CTL response that was significantly above back 
ground levels, the response did not exhibit an enhanced 
magnitude of lysis or more rapid kinetics of induction when 
compared with that of the RR-containing construct (data not 
shown). This finding Suggests that intracellular furin likely 
plays a leSS Significant role, or perhaps no role, in the 
processing of the epitope-C5a agonist construct than other 
intracellular proteases with Specificity for basic or dibasic 
residues. 
0201 Antibodies to the HBSAg CTL epitope or the C5a 
agonist are not produced by immunization with the HBSAg 
CTL epitope-C5a agonist constructs. Previous Studies 
showed that immunization of mice in the presence of 
additional adjuvant with MUC1 epitope-C5a agonist and 
opioid receptor epitope-C5a agonist constructs (see previous 
examples) induced antibody responses to the MUC1 and 
opioid receptor epitopes and the full-length, intact proteins. 
Thus, it was of interest to determine whether Sera from mice 
immunized with the control peptides and epitope-C5a ago 
nist constructs contained antibody directed against any of 
the peptides. Mice were bled at various times following 
injection and the Sera from all groups were tested by ELISA 
for reactivity with YSFKPMPLaR (SEQ ID NO: 1), 
IPOSLDSWWTSL (SEQ ID NO: 12), IPOSLDSW 
WTSLRR (SEQ ID NO: 18), and IPQSLDSWWTSLRRYS 
FKPMPLaR (SEQ ID NO: 14). These analyses failed to 
show binding to either the C5a agonist or the CTL epitopes 
(optical densities equal to normal mouse Serum at a 1:50 
dilution of the Serum). However, Sera taken from mice 
following three injections of IPOSLDSWWTSLRRYSFKP 
MPLaR (SEQ ID NO: 14) yielded an ELISA titer of 1:1600 
against the immunizing peptide, but did not bind the free 
peptides IPOSLDSWWTSLRR (SEQ ID NO: 18) or 
YSFKPMPLaR (SEQ ID NO: 1). These results suggest that 
the C5a-active, RR-containing construct contributes to the 
formation of a neo-B cell epitope that is presented via the 
class II pathway. 
TABLE 3 
Immunogen Activity in Smooth Muscle Contraction 
of Human Umbilical Artery 
ECso 
Peptide (SEQ ID NO:) pD, E SE (um) 
C5a 8.77 O.14 O.OO2 
YSFKPMPLaR (1) 6.99 0.22 O.O10 
IPOSLDSWWTSLYSFKPMPLaR (13) 6.68 0.17 O.21 
IPOSLDSWWTSLRRYSFKPMPLaR (14) 6.79 0.31 O161 
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TABLE 3-continued 
Immunogen Activity in Smooth Muscle Contraction 
of Human Umbilical Artery 
ECso 
Peptide (SEQ ID NO:) pD, E SE (um) in 
YSFKPMPLaRRRIPQSLDSWWTSL (16) 
IPOSLDSWWTSLRRYSFKPMPLaRG (17) 
IPOSLDSWWTSLRVRRYSFKPMPLaR 
(15) 
4.41 O.O6 39.4 3 
5.17 O.13* 6.78 3 
6.67 + 0.22 O.18 3 
pD = -log Ecs (M) expressed as mean it SE 
ECso concentration of peptide resulting in 50% maximum contraction 
in represents the number of measurements performed 
*significant change from YSFKPMPLaR, P < 0.05 
0202) 
TABLE 4 
Immunogen Activity in MPO Release for Human PMNS 
ECso 
Peptide (SEQ ID NO:) pD, E SE (um) in 
C5a 8.50 it 0.39 O.OO3 3 
YSFKPMPLaR (1) 5.88 O.17 132 3 
IPOSLDSWWTSLYSFKPMPLaR (13) 5.80 - 0.04 1.58 3 
IPOSLDSWWTSLRRYSFKPMPLaR (14) 6.27 + 0.29 0.54 3 
YSFKPMPLaRRRIPQSLDSWWTSL (16) >3 >1 mM 3 
IPOSLDSWWTSLRRYSFKPMPLaRG 5.59 + 0.28 2.56 3 
(17) 
IPOSLDSWWTSLRVRRYSFKPMPLaR 5.61 - 0.19 2.15 3 
(15) 
pD = -log Ecso (M) expressed as mean it SE 
ECso concentration of peptide resulting in 50% maximum release of 
myeloperoxidase 
in represents the number of measurements performed 
This peptide displayed partial agonist activity up to 1 mM achieving 49 it 
9% of the maximum C5a-induced enzyme release (P > 0.05) compared to 
YSFKPMPLaR (SEQ ID NO: 1). 
0203) 
TABLE 5 
Immunogen Binding Affinity for CSaRS On Human PMNS 
ECso 
Peptide (SEQ ID NO:) pD, E SE (um) in 
CSa 9.43 - 0.11 O.OOO4 3 
YSFKPMPLaR (1) 5.63 - 0.10 2.34 3 
IPOSLDSWWTSLYSFKPMPLaR (13) 5.43 - 0.16 3.69 3 
IPOSLDSWWTSLRRYSFKPMPLaR (14) 6.38 O.17* O.416 3 
YSFKPMPLaRRRIPOSLDSWWTSL (16) 3.33 O.O9* 465 3 
IPOSLDSWWTSLRRYSFKPMPLaRG 4.77 O.33* 17.0 3 
(17) 
IPOSLDSWWTSLRVRRYSFKPMPLaR 6.28. O.14 0.529 3 
(15) 
pD = -log Ecs (M) expressed as mean it SE 
ECso concentration of peptide resulting in 50% inhibition of 'I-C5a 
binding 
in represents the number of measurements performed 
*Significant change from YSFKPMPLaR, P < 0.05. 
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0204) 
TABLE 6 
Percent Specific Lysis of "Cr-Labeled P815S 
Target Cells from Mice Immunized with Various 
HBSAg CTL Epitope/C5a Agonist Peptides. 
% Specific Lysis 
Peptide (SEQ ID NO:) (ug Effector: Target Ratio 
injected) SO:1 25:1 12.5:1 6.25:1 
IPOSLDSWWTSL (12) (25) 7 5 3 3 
IPOSLDSWWTSLYSFKPMPLaR (13) 6 4 2 1. 
(47) 
IPOSLDSWWTSLRR (18) (25) 2 2 1. O 
IPOSLDSWWTSLRRYSFKPMPLaR 32 23 14 9 
(14) (42) 
YSFKPMPLaR(1) (25) 1. 2 O 1. 
IPOSLDSWWTSL (12) (25) + 1. 2 1. 1. 
YSFKPMPLaR(1) (25) 
IPOSLDSWWTSLRR (18) (25) + 2 O O O 
YSFKPMPLaR(1) (25) 
Normal Spleen Cells 1. 1. 1. O 
The CTL response was measured against the H-2' cell line (P815S) a 
transfectant that expresses the HBs.Ag. Normal P815 cells were used as a 
measure of non-specific lysis. % lysis against 'Cr-labeled P815 targets 
ranged between 0-5% at a 50:1 effector-to-target ratio (data not shown). 
BALB/c mice were injected s.c. with the indicated peptides in PBS. Mice 
were boosted on day 21 and spleen cell suspensions from each group were 
prepared on day 42 and restimulated as in vitro cultures for 4 days in the 
presence of HBs.Ag Se peptide, IPQSLDSWWTSL. 
0205 Discussion: 
0206 AS can be seen from the results presented above, 
the conformationally biased C5a agonist YSFKPMPLaR 
(SEQ ID NO: 1) serves as an effective molecular adjuvant, 
in this case by inducing antigen-specific CTL responses 
against a well-defined T cell epitope derived from the 
HBSAg. The CTL responses were CD8 and were observed 
only in mice that were immunized with C5a-active con 
structs in which the HBSAg CTL epitope was covalently 
attached to the N-terminus of YSFKPMPLaR (SEQ ID NO: 
1) (i.e., IPOSLDSWWTSLRRYSFKPMPLaR(SEQID NO: 
14) and IPQSLDSWWTSLRVRRYSFKPMPLaR (SEQ ID 
NO: 15)). This arrangement leaves the biologically impor 
tant conformational features in the C-terminal region of 
YSFKPMPLaR (SEQID NO: 1) free to interact with C5aRs 
expressed on the cells involved in the immune responses and 
underScores the necessity of C5a agonist activity in the 
generation of the observed CTL response. However, the 
presence of C5a agonist activity in the epitope-C5a agonist 
constructs alone was not Sufficient in generating HBSAg 
specific CTL responses. This was indicated by the lack of a 
CTL response in mice immunized with IPQSLDSW 
WTSLYSFKPMPLaR (SEQ ID NO: 13), despite the fact 
that this construct behaved as a full agonist of C5a. It is 
noteworthy that this C5a-active construct lacked a protease 
Sensitive linker Sequence Separating the epitope moiety from 
the C5a agonist moiety that was present in the two C5a 
active constructs that generated a CTL response-either the 
double-Arg (RR) or the furin protease-specific sequence 
RVRR (SEQ ID NO: 19). That CTL responses were 
observed only in mice immunized with C5a-active con 
Structs that contained these protease-Sensitive Sequences 
between the epitope and C5a agonist moieties Supports the 
concept that during the internalization of the C5aR/ligand 
complex an intracellular cleavage event may separate the 
epitope from the agonist to facilitate the entry of the epitope 
into intracellular antigen presentation pathways. It should be 
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noted that the failure of the free HBSAg peptide epitope to 
elicit a CTL response could be attributable to degradation 
after injection of internalization. Thus, it might be consid 
ered that the attachment of the epitope peptide to the 
N-terminus of the RR-containing C5a agonist peptide might, 
in part, reduce the Sensitivity of the epitope to degradative 
effects. Such stabilization of the CTL epitope could, in part, 
contribute to the effectiveness of the co-linear RR-contain 
ing constructs. However, it is unlikely that Such a phenom 
enon represents the Sole mechanism involved Since blocking 
the C-terminus of the C5a agonist moiety in these constructs 
abrogates their ability to elicit a CTL response, thereby 
indicating an essential role for C5a agonist activity in the 
observed responses. 
0207. It is also noteworthy that the C5a-active constructs 
IPOSLDSWWTSLRRYSFKPMPLaR (SEQ ID NO: 14) 
and IPOSLDSWWTSLRVRRYSFKPMPLaR (SEQ ID NO: 
15) induced robust CTL activity after a 2 boost in the 
absence of any added adjuvant. This observation Suggests 
that the C5a agonist moiety is capable of eliciting the T cell 
help necessary to induce the observed CD8 CTL response. 
It is likely that this T cell involvement emanates from the 
ability of the C5a agonist moiety to induce the release of 
immunopotentiating cytokines from C5aR-bearing APCs 
with which the epitope-C5a agonist constructs interact. This 
Supposition is Supported by the fact that C5a has been shown 
to induce the synthesis and release of IL-1 B, IL-20), IL-8, 
and IL-12 from human monocytee and IL-1B, IL-6, IL-8, 
IL-12, TNF-C, and IFN-Y from human dendritic cells. The 
C5a agonist moiety, therefore, appears capable of both 
targeting the attached epitope to C5aR-bearing APCs and 
eliciting the appropriate immunopotentiating activity. Thus, 
the YSFKPMPLaR(SEQID NO: 1) moiety of the constructs 
used in these immunizations can be viewed as a molecular 
entity that embodies adjuvant properties characteristic of 
both a “targeting vehicle' and an “immunomodulator”. 
Finally, mice immunized with YSFKPMPLaR (SEQID NO: 
1) containing constructs displayed no outward physical signs 
that would be characteristic of a C5a-mediated anaphylactic 
response. This in vivo use of YSFKPMPLaR (SEQ ID NO: 
1) and lack of associated toxicity in consistent with the 
response-Selective activities that have been observed in 
vitro. 
0208. The results described herein are consistent with a 
mechanism described in the previous examples. The 
YSFKPMPLaR (SEQ ID NO: 1) moiety of the HBSAg 
constructs interacts with C5aRS expressed on the Surface of 
APCs to induce the synthesis and release of cytokines that 
activate T cells. Following C5aR activation and cytokine 
release, the C5aR/ligand complex internalizes allowing 
intracellular proteases to Separate the HBSAg epitope from 
the C5a agonist by cleaving at the double-Arg (RR) or 
furin-specific sequence (RVRR (SEQ ID NO: 19)) that 
Separate these two moieties. The HBSAg epitope then asso 
ciates with MHC class I determinants that are subsequently 
expressed on the APC surface. While this mechanism of 
CTL induction by the C5a agonist-containing constructs 
remains is but one of Several possibilities, it may involve a 
novel pathway of exogenous MHC class I antigen presen 
tation. Since it had been generally assumed that class 
I-mediated antigen presentation involved the generation of 
peptides from endogenously Synthesized proteins, the find 
ing that extracellular Soluble proteins could be taken up by 
professional phagocytes (macrophages and dendritic cells), 
processed in the cytoplasm or perhaps endoSomes to yield 
antigenic peptides, which are presented in association with 
MHC class I molecules, is of considerable Significance. 
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Presentation of extracellular antigens would be expected to 
be most efficient when they are particulate in nature and, 
consequently, are more Susceptible to phagocytosis by mac 
rophages and dendritic cells. In the case of the C5a agonist 
constructs, it is possible that targeting the C5aR on Such cells 
might accomplish a similar enhancement of presentation in 
the MHC class I pathway. Such a proposal Seems especially 
tenable in light of the recent findings that Subunits of Several 
bacterial toxins, especially anthrax toxin, when coupled to 
protein and peptide antigens, are capable of effecting inter 
nalization of the antigens and delivering them into the class 
I presentation pathway with resultant antigen-specific CTL 
production. Finally, it is noteworthy that a proteoSome 
independent, furin-dependent Viral antigen processing path 
way where cleavage occurs in the Golgi or post-Golgi 
Secretory pathway has been recently described. Again, this 
finding Suggests that interSection of internalized antigens/ 
peptides with elements of the anterograde Secretory pathway 
(endoSomal or trans-Golgi region), as may occur with C5aR/ 
ligand complexes, could result in processing events and 
asSociation with unoccupied class I molecules that are in 
transit through this pathway. 
0209 Although an exogenous pathway of intracellular 
processing of the epitope-RR-C5a agonist constructs 
appears to be a plausible mechanism, it is also possible that 
the HBSAg epitope peptide is introduced onto MHC class I 
determinants expressed on the surface of the APC. Thus, the 
co-linear peptides containing the RR-C5a agonist moiety 
could bind to the surface of APCs and, after proteolytic 
cleavage of the Scissile linkage, the HBSAg CTL epitope 
could displace lower affinity endogenous peptide in cell 
Surface class I molecules. At present, the relative contribu 
tion of extracellular and intracellular processing events in 
CTL induction mediated by the C5a agonist moiety has not 
been assessed. Further in vitro experiments are being 
designed to address this issue. 
22 
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0210. In contrast to formulating peptide and/or protein 
antigens as particulates or as toxin Subunit-conjugates or 
other derivatives, the C5a agonist peptide, rather than Serv 
ing as an inert carrier, might provide the added benefit of 
delivering immunopotentiating Signals. Accordingly, Such 
constructs, containing either covalently linked peptides or 
proteins, might be of particular benefit in those situations 
where the target proteins or peptides are nominally immu 
nogenic irrespective of the delivery vehicle or construct 
employed. In the case of peptides, a further advantage of this 
technology is that the C5a agonist constructs are relatively 
Simple to produce and do not require recombinant technolo 
gies and associated protein purification methodologies or 
Specialized formulation procedures. 
0211 The antigen-specific responses to well-defined T 
cell and B cell epitopes observed in our Studies Support the 
potential use of YSFKPMPLaR (SEQ ID NO: 1) and other 
response-Selective C5a agonists as molecular adjuvants for 
inducing a defined spectrum of humoral and/or cellular 
responses against peptide, protein, and, possibly, non-pro 
tein antigens. Such as possibility would provide a broad 
based adjuvant/delivery technology that would be applicable 
to a number of infectious and oncologic diseases in either 
prophylactic or therapeutic Settings. 
EXAMPLE 6 
Evaluation of Nicotine Vaccine Compositions for 
Recruitment and Activation of Antigen Presenting 
Cells (APCs) and Stimulation of an Immune 
Response in Mice 
0212 i. Construction of the Nicotine Vaccine Composi 
tions. The nicotine Vaccine composition was Synthesized by 
first generating the nicotine hapten 5 by the route shown in 
Scheme 1. 
SCHEME 1. 
HOOC HO 
21 s N O c, d 21 s N 
-- 
s CH s CH 
2 3 
fg 
O 
--- HN N 
21 s N 
Key: (a) CH3NH2, 3A molecular sieves; (b) succinic anhydride, A, (c) MeOH, H2SO4 (cat.) (d) LAH; 
(e) TosCI, EtN: (f) NaNa, DMF, A; (g) LAH; (h) succinic anhydride. 
US 2005/0O89524 A1 
0213. Once generated, 5 was then converted into an 
activated ester and coupled to the N-terminus of YSFKP 
MPLaR (the molecular adjuvant, SEQ ID NO:1) and 
YKQGGFLGLYSFKPMPLaR (a B cell epitope-molecular 
adjuvant construct, SEQ ID NO:2) during the solid-phase 
Synthesis of these peptides according to Scheme 2. 
23 
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HN-YKQGGFLGLYSFKPMPLaR 
SCHEME 2 
O 
O-HBTU 
NH 
O 
-- HN-YSFKPMPLaR 
N '. n 
CH 2 
N 
O 
NH-YSFKPMPLaR 
NH 
O 
-YKOGGFLGLYSFKP 
'' N 
CH 2 
N 
NH-YSFKPMPLaR 
NH Acidolysis 
-YKOGGFLGLYSFKPMPLaR 
O 
Nicotine Vaccine Constructs 
0214. The two C5a-active nicotine vaccine constructs 
(Nic-YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID NO:2) 
and Nic-YSFKPMPLaR (Nic-SEQ ID NO:1)) were purified 
and characterized by Standard methods as detailed above. 
0215 ii. Animal Models. Five groups of male Wistar rats 
(ca 275 g) were immunized every other week with: 1) PBS 
2) Nic-YSFKPMPLaR(Nic-SEQID NO:1), 3) Nic-YSFKP 
MPLaR (Nic-SEQ ID NO: 1) in Freund's adjuvant, 4) Nic 
YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID NO:2), and 5) 
Nic-YKQGGFLGLYSFKMPMPLaR (Nic-SEQ ID NO:2) 
in Freund's adjuvant. Primary immunizations were accom 
plished by Subcutaneous (s.c.) and intrapertioneal (i.p.) 
injection of 100 lug of the peptides as indicated above in the 
presence or absences of complete Freund's adjuvant. Boost 
ing was performed in identical fashion at two-week internals 
with 100 lug of the peptides in the presence of absence of 
Freund's adjuvant. Sera were obtained by retro-orbital sinus 
puncture one week after the third injection. The presence of 
anti-nicotine antibodies in immune Serum was demonstrated 
by Standard enzyme-linked immunosorbant assay (ELISA) 
using a conjugate of 5 (Nic) to various proteins and their 
unmodified controls as the coating antigens. 
0216) iii. Results 
TABLE 7 
Reactivity of antiserum from rats immunized with 
nicotine-modified peptide immunogens on bovine serum 
albumin (BSA) unmodified or modified with nicotine. 
Antigen Coating the Plate 
Modified Minus 
Raw Data Unmodified 
ng/ml ng/ml 
Immunogen BSA BSA-Nic BSA BSA-Nic 
PBS O O O O 
CSa-Nic 466 4,320 O 3,854 
C5a-Nic 1,304 8,986 O 7,682 
Freunds 
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TABLE 7-continued 
Reactivity of antiserum from rats immunized with 
nicotine-modified peptide immunogens on bovine serum 
albumin (BSA) unmodified or modified with nicotine. 
Antigen Coating the Plate 
Modified Minus 
Raw Data Unmodified 
ng/ml ng/ml 
Immunogen BSA BSA-Nic BSA BSA-Nic 
B-cell-C5a-Nic 1298 35,241 O 33,943 
B-Cell-C5a-Nic O 15,371 O 15,371 
Freund's 
Nic-YSFKPMPLaR (SEQ ID NO: 1) 
Nic-YKQHGGFLGLYSFKPMPLaR (SEQ ID NO: 2) 
0217. As shown in Table 7, only those rats immunized 
with C5-a-active constructs (Nic-YSFKPMPLaR (Nic-SEQ 
ID NO:1), and Nic-YKQGGFLGLYSFKMPMPLaR (Nic 
SEQ ID NO:2)) generated significant concentrations (ng/m;) 
of anti-Nic antibodies. Although good results were obtained 
in the presence of adjuvant (Freund's), it is noteworthy that 
concentrations of anti-Nic antibodies were generated in the 
absence of Freund's adjuvant. 
0218. As shown in FIG. 7, when these antisera were 
tested on other nicotine-modified peptides, Nic-YSFKPM 
PLaR (C5a-Nic, (SEQ ID NO:1)) and Nic-YKOGGFLGL (B-Cell-Nic, (SEQ ID NO:6)), the antibody reactivity was 
still highest in the serum from rats immunized with Nic 
YKQGGFLGLYSFKPMPLaR (SEQ ID NO:2) in the pres 
ence of Freund's adjuvant (172,647 ng/ml). However, Nic 
YSFKPMPLaR (C5a-Nic, (SEQ ID NO:1)) in the presence 
and absence of Freund's adjuvant also induced responses to 
nicotine as determined by reactivity to C5a-Nic (Nic-YS 
FKPMPLaR, (SEQ ID NO:1)) and the B-Cell-Nic (Nic 
YKQGGFLGL, (SEQ ID NO:6)). 
EXAMPLE 7 
Attenuation of Nicotine Induced Behavioral Effects 
in Rats 
0219. In order to determine the ability of the nicotine 
vaccine compositions of the invention to attenuate behav 
ioral effects of nicotine addiction, 16 male Sprague-Dawley 
rats weighing approximately 300 grams were divided into 
two groups (with eight rats in each group) and each group 
was administered a different treatment regiment. All nicotine 
compositions were prepared as described in Example 6. In 
one treatment group, eight rats were vaccinated with 1000 
mg of Nic-YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID 
No.2) (500 mg s.c. and 500 mg i.p.) dissolved in sterile 
saline and boosted in identical fashion every week for 2 
weeks. The Second group of eight was sham immunized and 
boosted with sterile Saline. Following the last boost, the rats 
100% free-feeding weight was slowly decreased by 15% 
across a week (i.e., target weight). This target weight insured 
that the rats would seek 32% (w/v) liquid Sucrose in the 
experimental apparatus. On dayS 1 to 3, rats were taught to 
access 4-Second deliveries of liquid Sucrose in the apparatus. 
For the following 16 days, rats in the vaccinated and 
non-vaccinated groups were shifted to a or nicotine) inter 
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mixed in a quasi-random fashion within two 8-Session 
cycles that included 4 Saline and 4 nicotine Sessions. On 
Saline Sessions, rats were injected S.c. with Saline (0.9% 
NaCl) and placed in the experimental apparatus for 20 
minutes. Following variable delays, 8 lights were presented 
for 15 seconds, but no food was delivered. Saline sessions, 
therefore, provided a baseline with which to determine if the 
vaccine affected behavior independent of the presence of 
nicotine. On nicotine Sessions, rats were injected S.c. with 
nicotine (0.4 mg/kg base) and placed in the apparatus for 20 
minutes. The light cues were followed by 4-Second access to 
the Sucrose. Thus, nicotine plus light Signaled food access, 
light alone (i.e., Saline Sessions) signaled no food. 
0220. In early Sessions, food Seeking, as measured by 
breaks in an infrared beam where Sucrose is accessed 
(hereinafter "dipper entries”), should be high. Dipper 
entries, however, should decrease in Saline Sessions because 
no Sucrose is being delivered. Indeed, food Seeking System 
atically decreased acroSS Saline Sessions in a pattern Similar 
for vaccinated and non-vaccinated rats (FIG. 8, Panel A). 
This outcome indicates that the vaccine does not differen 
tially affect behavior in this preparation when nicotine is not 
present. In contrast, there is a clear difference in food 
Seeking behavior in the nicotine Sessions. Dipper entries 
remained high in non-vaccinated rats likely reflecting a 
"Summation' of food-seeking behavior maintained by occa 
Sional Sucrose delivery and the psychomotor Stimulant 
effects of nicotine. Notably, dipper entries in vaccinated rats 
decreased below the levels of non-vaccinated rats. The 
results depicted in FIG. 8 demonstrate the ability of the 
nicotine vaccine composition to attenuate the centrally 
mediated psychomotor effects of nicotine in vaccinated rats 
during the first cycle of training. This interpretation is 
Supported by an omnibus 3-way mixed factorial analysis of 
variance with Group (Vaccinated VS. non-vaccinated) as a 
between-Subjects factor, and Session (1 to 4) and Session 
Type (nicotine or Saline) as within-Subject factors. The main 
effects of Group, Session, and Session Type were all Statis 
tically Significant, pS less than or equal to 0.002. Further, the 
Group X Session Type interaction, F(1,14)=6.31, p=0.025 
and the Session X Session Type interaction, F(3,42)=5.024, 
p=0.005, were significant. The Session X Group and the 
Session X Group X Session Type interactions were not 
Significant, p greater than or equal to 0.34. Subsequent 
Statistical contrasts to investigate the Source of the Group X 
Session Type interaction were limited to comparing vacci 
nated and non-vaccinated rats within each Session type. 
Vaccinated rats displayed Significantly leSS dipper entries 
than non-vaccinated rats on nicotine Sessions 2 and 3, ps 
less than 0.05, indicating that the vaccine was effective at 
attenuating the effects of nicotine in this animal model. 
0221 FIG. 8, Panel B shows the index of learning 
elevation Score for the first light (before Sucrose is given). A 
positive elevation Score indicates learning in that more 
dipper-entries are occurring during the 15-Second light than 
in a comparable time just before the light occurred (light 
dipper entries minus pre-light dipper entries). AS can be 
Seen, by the end of the first cycle rats are just learning that 
Sucrose is being delivered during the light only on nicotine 
Sessions. This indeX does not differ between vaccinated and 
non-vaccinated rats. Analyses confirm these observations. 
There was a main effect of Session and Session Type, pleSS 
than or equal to 0.012. No other factors were significant, p 
greater than or equal to 0.076. Notably, the vaccine did not 
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produce a general insensitivity to Sucrose reward. Evidence 
for this comes from the Similar acquisition rate of anticipa 
tory dipper entries in vaccinated and non-vaccinated rats. 
0222 AS training continued and rats learned to discrimi 
nate nicotine sessions from saline sessions (FIG. 8, Panel B), 
the effect of the vaccine on total number of dipper entries in 
the nicotine sessions was lost (FIG. 8, Panel A). For the total 
number of dipper entries only the main effect of Session 
Type was significant, p<0.001. For the elevation score only 
the main effect of Session Type and the Session Type X 
Session interaction were significant, pS greater than or equal 
to 0.032. Overall, these data indicate that dipper entries 
(food seeking) are coming under the control of the nicotine 
cue and that the vaccine, albeit effective, does not prevent 
enough of the nicotine from acting as an interoceptive cue. 
0223 Six rats from each of the above treatment groups (i.e., nicotine exposed-vaccinated and nicotine exposed 
non-vaccinated) were bled and Serum obtained for Studies on 
antibody titer and specificity. The titer was determined by 
assessing the reactivity (optical density or “OD”) of each 
antiserum on bovine serum albumin (BSA) and BSA modi 
fied with the nicotine hapten (BSA-Nicotine). The OD of the 
antiserum on BSA was Subtracted from its OD on BSA 
Nicotine, and the last difference in OD that resulted in 
greater than a 0.100 reading was considered the final titer for 
that antiserum. As shown in FIG. 9, the antibody titers of the 
Six rats in the vaccinated group averaged 1:223. In contrast, 
the non-vaccinated group of rats had antibody titers of leSS 
than 1:50, as this was the lowest dilution utilized in these 
studies and none of the rats were above this dilution. Thus, 
a significant increase in the antibody titers of rats immunized 
with Nic-YKQGGFLGLYSFKPMPLaR (Nic-SEQ ID 
No.2) was determined. 
0224) Specificity of the vaccinated rat antiserum was 
addressed using a competitive ELISA. Briefly, a dilution for 
each rat was determined on the BSA-nicotine that resulted in 
50% maximum (0.800) OD after 30 minutes. To this dilu 
tion, different concentrations of nicotine or phosphate buff 
ered Saline (i.e., no inhibitor), were added to the antiserum 
and allowed to incubate overnight at 4 C. The next day, 
these samples were added to ELISA plates coated with 
BSA-nicotine and the reactivity of the antiserum plus inhibi 
tor was determined. As shown in FIG. 10, nicotine began to 
inhibit the antibody response between 250 and 500 pM, and 
reached maximum inhibition between 8,000 and 10,000 pM. 
These data demonstrate that the antibodies are specific for 
nicotine. 
0225 Collectively, these results show not only that the 
nicotine vaccine (Nic-YKQGGFLGLYSFKPMPLaR (Nic 
SEQ ID No.2)) is capable of generating anti-nicotine anti 
bodies in rats, but is also capable of attenuating nicotine 
induced behavioral effects in the presence of high 
concentrations of nicotine (0.4 mg/kg). Moreover, the 
immune response retains its resiliency over the course of 
approximately 2 months time. Most remarkable is that fact 
that these in vitro and in Vivo immune responses were 
generated in the complete absence of any added adjuvant. 
Thus, this vaccine design generates immune responses with 
the desired nicotine Specificity and longevity even in the 
presence of large amounts of nicotine. 
0226. While certain preferred embodiments of the 
present invention have been described and Specifically 
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exemplified above, it is not intended that the invention be 
limited to such embodiments. Various modifications may be 
made to the invention without departing from the Scope and 
Spirit thereof as Set forth in the following claims. 
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1. A compound comprising a molecular adjuvant linked to 
a nicotine hapten, the molecular adjuvant comprising a 
targeting ligand having binding affinity for a characteristic 
determinant of an antigen presenting cell, the targeting 
ligand being functionally linked to the nicotine hapten, 
whereby binding of the molecular adjuvant to the antigen 
presenting cell determinant activates the antigen presenting 
cell, effecting delivery of the nicotine hapten to an antigen 
presenting pathway of the antigen presenting cell. 
2. The compound of claim 1 wherein the targeting ligand 
of the molecular adjuvant binds Specifically to a determinant 
comprising an immunomodulatory receptor of the antigen 
presenting cell. 
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3. The compound of claim 1 wherein the targeting ligand 
of the molecular adjuvant binds Specifically to a receptor 
Selected from the group consisting of C5a receptor, IFN 
gamma receptor, CD21 (C3d) receptor, CD64 (FcgRI) 
receptor, and CD23 (FceRII) receptor. 
4. The compound of claim 1 wherein the targeting ligand 
of the molecular adjuvant binds Specifically to a C5a recep 
tor and is Selected from the group consisting of C5a and a 
peptide agonist analog of C5a comprising the C-terminal ten 
residues of C5a. 
5. The compound of claim 1 wherein the targeting ligand 
of the molecular adjuvant is a peptide comprising the 
sequence YSFKKPMPLaR, which is SEQ ID NO:1. 
6. The compound of claim 1 wherein the targeting ligand 
of the molecular adjuvant is a peptide comprising the 
sequence YKQGGFLGLYSFKPMPLaR, which is SEQ ID 
NO:2. 
7. The compound of claim 1 wherein the nicotine hapten 
has a structure corresponding to: 
O-HBTU. 
NH 
8. The compound of claim 1 wherein the nicotine hapten 
has a structure Selected from the group consisting of 
(a) 
HOOC 
(b) 
N 
N-cool and 
N 
(c) 
21 w 
N 
N 
H 
21 w N 
2 
N CH 
9. The compound of claim 1 wherein the nicotine hapten 
is linked to the molecular adjuvant by a Spacer moiety. 
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10. The compound of claim 4 wherein the nicotine hapten 
is linked to the N-terminus of the peptide comprising the 
molecular adjuvant. 
11. The compound of claim 10 wherein the nicotine 
hapten is linked to the N-terminus of the peptide comprising 
the molecular adjuvant by an amide bond. 
12. The compound of claim 1 wherein the compound has 
a structure corresponding to: 
NH-YSFKPMPLAR. 
NH 
13. The compound of claim 1 wherein the compound has 
a structure corresponding to: 
O 
NH-YKOGGFLGLYSFKPMPLaR. 
NH 
O 
t N 
CH 2 
N 
14. A vaccine composition comprising the compound of 
claim 1. 
15. A vaccine composition comprising the compound of 
claim 4. 
16. A vaccine composition comprising the compound of 
claim 12. 
17. A vaccine composition comprising the compound of 
claim 13. 
18. A method of treating nicotine addiction in a patient in 
need of Such treatment, the method comprising administer 
ing to the patient a therapeutically effective amount of the 
compound of claim 1. 
19. A method of treating nicotine addiction in a patient in 
need of Such treatment, the method comprising administer 
ing to the patient a therapeutically effective amount of the 
compound of claim 4. 
20. A method of treating nicotine addiction in a patient in 
need of Such treatment, the method comprising administer 
ing to the patient a therapeutically effective amount of the 
compound of claim 12. 
21. A method of treating nicotine addiction in a patient in 
need of Such treatment, the method comprising administer 
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ing to the patient a therapeutically effective amount of the 
compound of claim 13. 
22. A method of preventing nicotine addiction in a patient 
in need of Such treatment, the method comprising adminis 
tering to the patient a therapeutically effective amount of the 
compound of claim 1. 
23. A method of treating nicotine addiction in a patient in 
need of Such treatment, the method comprising administer 
ing to the patient a therapeutically effective amount of the 
compound of claim 4. 
24. A method of treating nicotine addiction in a patient in 
need of Such treatment, the method comprising administer 
ing to the patient a therapeutically effective amount of the 
compound of claim 12. 
25. A method of treating nicotine addiction in a patient in 
need of Such treatment, the method comprising administer 
ing to the patient a therapeutically effective amount of the 
compound of claim 13. 
26. A method of producing antibodies to a nicotine 
hapten, the method comprising: 
(a) immunizing an animal with an immunogenic effective 
amount of the compound of claim 1, 
(b) isolating antibodies from the Sera of the animal; and 
(c) recovering the isolated antibodies. 
27. The method of claim 26 wherein the targeting ligand 
of the molecular adjuvant of Said compound binds Specifi 
cally to a C5a receptor and is Selected from the group 
consisting of C5a and a peptide agonist analog of C5a 
comprising the C-terminal ten residues of C5a. 
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28. The method of claim 26 wherein said compound has 
a structure corresponding to: 
NH-YSFKPMPLAR. 
NH 
29. The method of claim 26 wherein said compound has 
a structure corresponding to: 
O 
NH-YKOGGFLGLYSFKPMPLaR. 
NH 
O 
'', N 
CH 2 
N 
